				|

		52014PC0028

			Togra le haghaidh RIALACHÁIN Ó PHARLAIMINT NA hEORPA AGUS ÓN gCOMHAIRLE lena leasaítear Rialachán (CE) Uimh. 715/2007 agus Rialachán Uimh. 595/2009 maidir le hastaíochtaí truailleán ó fheithiclí bóthair a laghdú /* COM/2014/028 final - 2014/0012 (COD) */

			   	MEABHRÁN MÍNIÚCHÁIN
"1.         COMHTHÉACS AN TOGRA
Is é aidhm an togra seo méid áirithe leasuithe
a thabhairt isteach ar Rialachán (CE) Uimh. 715/2007
agus ar Rialachán (CE) 595/2009 maidir le
hastaíochtaí truailleán ó fheithiclí bóthair a laghdú. Tá an dréacht-togra seo
dírithe ar na réimsí sin ina gcuireann cliseadh ar an margadh nó cliseadh
rialála bac ar na dúshláin uileghabhálacha i gcomhthéacs Chlár Oibre an AE
maidir le cáilíocht aeir agus Rialú níos Fearr.
2.           TORTHAÍ AN CHOMHAIRLIÚCHÁIN
LEIS NA PÁIRTITHE LEASMHARA AGUS MEASÚNUITHE TIONCHAIR
Déantar na bearta a chothromú idir an tionchar
a bheidh acu ar an gcomhshaol, agus an t‑ualach a
chuirfidh siad ar thionscal. Tacaíonn an Measúnú Tionchair atá ag gabháil leis
seo le héifeachtúlacht costas na mbeart.
3.           EILIMINTÍ DLÍ AN TOGRA
Tugtar isteach leis an togra seo méid áirithe
leasuithe ar Rialachán (CE) 715/2007 agus ar Rialachán (CE) Uimh. 595/2009 maidir le hastaíochtaí truailleán ó fheithiclí bóthair a
laghdú.
2014/0012 (COD)
Togra le haghaidh
RIALACHÁIN Ó PHARLAIMINT NA hEORPA AGUS
ÓN gCOMHAIRLE
lena leasaítear Rialachán (CE)
Uimh. 715/2007 agus Rialachán Uimh. 595/2009 maidir le hastaíochtaí
truailleán ó fheithiclí bóthair a laghdú
(Téacs atá ábhartha maidir leis an LEE)
TÁ PARLAIMINT NA hEORPA AGUS COMHAIRLE
AN AONTAIS EORPAIGH,
Ag féachaint don Chonradh ar Fheidhmiú an
Aontais Eorpaigh, agus go háirithe Airteagal 114 de,
Ag féachaint don togra ón gCoimisiún Eorpach,
Tar éis dóibh an dréachtghníomh reachtach a
chur chuig na parlaimintí náisiúnta,
Ag féachaint don tuairim ó Choiste Eacnamaíoch
agus Sóisialta na hEorpa[1],

Ag gníomhú dóibh i gcomhréir leis
an ngnáthnós imeachta reachtach,
De bharr an méid seo a leanas:
(1)          D'fhonn na hualaigh nach gá
atá ar mhonaróirí feithicle a laghdú i gcás cineál‑cheadaithe ardán
feithicle a d'fhéadfaí a chumhdach le reachtaíocht maidir le feithiclí
tromshaothair agus feithiclí saothair éadroim, ba cheart go mbeifí in ann
feithiclí áirithe tromshaothair a cheadú i gcomhréir leis na ceanglais ar
fheithiclí saothair éadroim i ndáil lena n-astaíochtaí truailleán gan bhaint de
leibhéal na cosanta comhshaoil san Aontas.
(2)          Cé nach fios an mbíonn
éifeacht dhíreach dhíobhálach ag astaíochtaí meatáin ar shláinte an duine, gás
láidir ceaptha teasa is ea é. Dá bhrí sin, i gcomhréir leis an Teachtaireacht
ón gCoimisiún maidir le cur i bhfeidhm agus forbairt amach anseo reachtaíocht
an Chomhphobail maidir le hastaíochtaí feithicle ó fheithiclí saothair éadroim
agus rochtain ar fhaisnéis faoi dheisiú agus faoi chothabháil (Euro 5 agus 6)[2] agus le hAirteagal
14(1) de Rialachán (CE) 715/2007 ó Pharlaimint na hEorpa agus ón gComhairle[3], ba cheart don
Choimisiún cuimhneamh ar astaíochtaí meatáin a áireamh i ríomh astaíochtaí CO2.

 (3)         D'fhonn tabhairt isteach
feithiclí gáis nádúrtha a éascú, ba cheart an teorainn astaíochta atá ann faoi
láthair do lánhidreacarbóin (THC) a ardú agus ba cheart tionchar astaíochtaí
meatáin a chur san áireamh agus a shloinneadh i gcoibhéis CO2chun
críocha rialála agus faisnéise do chustaiméirí.
(4)          Astaíonn feithiclí díosail an
lae inniu méideanna móra méadaitheacha NO2 mar sciar d'astaíochtaí
iomláin NOx, rud nach rabhthas ag tnúth leis nuair a glacadh Rialachán (CE)
Uimh. 715/2007. Dealraíonn sé go mbaineann formhór na bhfadhbanna i ndáil
le cáilíocht aeir i gceantair uirbeacha le hastaíochtaí díreacha NO2.
Dá bhrí sin, ba cheart teorainn iomchuí ar astaíochtaí a thabhairt isteach.
(5)          Tugadh sall na teorainneacha
astaíochta atá ann faoi láthair le haghaidh CO agus lánhidreacarbón (THC) i
gcás inneall fuar a thosú ag teocht íseal ó cheanglais Euro 3 atá leagtha amach i dTreoir 98/69/CE ó Pharlaimint na hEorpa agus ón
gComhairle[4],
ach meastar go bhfuil siad as dáta anois i bhfianaise na teicneolaíochta
feithicle agus na riachtanas maidir le cáilíocht aeir atá ann anois. Ina
theannta sin, tugann na fadhbanna a bhaineann le cáilíocht aeir agus torthaí na
dtomhas ar astaíochtaí feithicle le fios go bhfuil gá teorainn iomchuí a
thabhairt isteach i ndáil le hastaíochtaí NOx/NO2. Dá bhrí sin, ba
cheart teorainneacha leasaithe astaíochta a thabhairt isteach de bhun Airteagal 14(5) de Rialachán (CE) Uimh. 715/2007.
(6)          An teorainn astaíochta atá
leagtha amach le haghaidh NH3 i Rialachán (CE) Uimh. 595/2009 ó Pharlaimint na hEorpa agus ón gComhairle[5], is ceanglas é atá ceaptha
leis an sciorradh amóinia a theorannú ó theicneolaíochtaí iarchóireála NOx a
bhaineann úsáid as imoibrí úiré chun NOx a dhí-ocsaídiú. Níor cheart an
teorainn luacha ar NH3 a chur i bhfeidhm, dá bhrí sin, ach ar na
teicneolaíochtaí sin agus níor cheart iad a chur i bhfeidhm ar innill adhainte
deimhní.
(7)          D'fhonn cuspóirí an AE maidir
le cáilíocht aeir a bhaint amach, agus chun a áirithiú go ndéantar iarracht
leanúnach astaíochtaí ó fheithiclí a laghdú, ba cheart an cumhacht chun
gníomhartha tarmligthe a ghlacadh i gcomhréir le hAirteagal 290 den Chonradh ar Fheidhmiú an Aontais Eorpaigh (CFAE) a tharmligean
chuig an gCoimisiún i ndáil leis na rialacha mionsonratihe maidir le cur i
bhfeidhm Rialachán (CE) Uimh. 715/2007 maidir leis an méid seo a leanas:
feithiclí de chatagóir M1, M2, N1 agus N2
ar mó a mais thagartha ná 2 610 kg, ach nach mó a n-uasmhais feithicle ná 5 000 kg, na
nósanna imeachta, tástálacha agus ceanglais shonracha is gá le haghaidh
cineál-cheadaithe, na ceanglais i ndáil leis an gcosc ar úsáid feistí sáraithe
a laghdaíonn éifeachtúlacht na gcóras rialaithe astaíochtaí a chur chun
feidhme, na bearta is gá chun oibleagáid monaróra rochtain neamhshrianta agus
chaighdeánaithe ar fhaisnéis faoi dheisiú agus faoi chothabháil feithiclí a chur
chun feidhme, faisnéis faoi mhais iomlán coibhéisí astaíochtaí CO2 a
chur in ionad na faisnéise faoi mhais astaíochtaí CO2 atá sa
deimhniú comhréireachta, luach teorann astaíochtaí lánhidreacarbóin (THC) le
haghaidh feithiclí adhainte deimhní, Rialachán (CE) Uimh. 715/2007 a leasú d'fhonn na luachanna teorantacha bunaithe ar mhais
cháithníneach a athchalabrú agus luachanna teorantacha bunaithe ar líon na
gcáithníní a thabhairt isteach ionas go mbeidh siad i gcomhchoibhneas
ginearálta leis na luachanna teorantacha bunaithe ar mhais do pheitreal agus do
dhíosal, nós imeachta tomhais leasaithe a ghlacadh maidir le cáithníní agus
luach teorann líon na gcáithníní, luach teorann le haghaidh astaíochtaí NO2
agus teorainneacha le haghaidh astaíochtaí ó sceithphíopaí ag teochtanna ísle
le haghaidh feithiclí a ceadaíodh a gcomhlíonadh le teorainneacha astaíochta
Euro 6. Ba cheart don Choimisiún a áirithiú, agus gníomhartha tarmligthe á
n-ullmhú agus á dtarraingt suas aige, go ndéanfar na doiciméid ábhartha a tharchur
go comhuaineach, go tráthúil agus go hiomchuí chuig Parlaimint na hEorpa agus
chuig an gComhairle.
(8)          Thug Conradh Liospóin deis
don reachtóir cumhacht a tharmligean chuig an gCoimisiún chun gníomhartha
neamhreachtacha a bhfuil feidhm ghinearálta leo a ghlacadh chun eilimintí
neamhriachtanacha áirithe de ghníomh reachtach a fhorlíonadh nó a leasú. I
bprionsabal, freagraíonn na bearta is féidir a chumhdach le tarmligean
cumhachtaí, dá dtagraítear in Airteagal 290(1) CFAE, dóibh sin a chumhdaítear
leis an nós imeachta rialúcháin lena ngabhann grinnscrúdú arna bhunú le
hAirteagal 5a de Chinneadh 1999/468/CE ón gComhairle[6]. Tá sé riachtanach, dá
bhrí sin, na forálacha i Rialachán (CE) Uimh. 715/2007 a dhéanann foráil maidir
leis an nós imeachta rialúcháin lena ngabhann grinnscrúdú a chur in oiriúint
d'Airteagal 290 CFAE.
(9)          Níor cheart go ndéanfadh
oiriúnú na bhforálacha i Rialachán (CE) Uimh. 715/2007
lena ndéantar foráil maidir le húsáid an nós imeachta rialúcháin lena ngabhann
grinnscrúdú d'Airteagal 290 CFAE difear do nósanna imeachta atá ar
feitheamh, ar chuir an coiste in iúl cheana féin a thuairim ina leith i
gcomhréir le hAirteagal 5a de Chinneadh 1999/468/CE roimh theacht i bhfeidhm an Rialacháin seo.
(10)        Chun dálaí aonfhoirmeacha a
áirithiú d'fhonn Airteagal 4(2) agus Airteagal (3) de
Rialachán (AE) Uimh. 715/2007 a chur chun feidhme, ba
cheart cumhachtaí cur chun feidhme a thabhairt don Choimisiún. Ba
cheart na cumhachtaí sin a fheidhmiú i gcomhréir le Rialachán (AE)
Uimh. 182/2011 ó Pharlaimint na hEorpa agus ón gComhairle[7].
(11)        Dá bhrí sin, ba cheart
Rialachán (CE) Uimh. 715/2007 agus Rialachán (CE) Uimh. 595/2009 a
leasú dá réir,
TAR ÉIS AN RIALACHÁN SEO A GHLACADH:
Airteagal 1
Leasaítear Rialachán (CE)
Uimh. 715/2007 mar seo a leanas:
(1) In Airteagal 2, cuirtear an méid seo a
leanas in ionad mhír 2:
"2. Tar éis na gníomhartha tarmligthe arna
nglacadh i gcomhréir leis an dara fomhír a fhoilsiú, agus arna iarraidh sin don
déantóir, beidh feidhm ag an Rialachán seo maidir le feithiclí de chatagóir M1,
M2, N1 agus N2 mar atá sainmhínithe in
Iarscríbhinn II a ghabhann le Treoir 2007/46/CE ó Pharlaimint na hEorpa agus ón
gComhairle* ar mó a mais thagartha ná 2 610 kg, ach nach mó a n-uasmhais feithicle ná 5 000 kg.
Tabharfar de chumhacht don Choimisiún gníomhartha
tarmligthe a ghlacadh i gcomhréir le hAirteagal 14a maidir leis na
rialacha mionsonraithe i ndáil leis an Rialachán seo a chur i bhfeidhm ar
fheithiclí de chatagóir M1, M2, N1 agus N2
mar atá sainmhínithe in Iarscríbhinn II a ghabhann le
Treoir 2007/46/CE ar mó a mais thagartha ná 2 610 kg, ach nach mó a n-uasmhais feithicle ná
5 000 kg. Áiritheoidh na gníomhartha tarmligthe go háirithe go
gcuiftear san áireamh go cuí i dtástálacha ar dhinimiméadair fonnaidh mais
oibríochtúil iarbhír na feithicle chun an táimhe choibhéiseach a chinneadh mar
aon le paraiméadair eile i ndáil le cumhacht réamhshocraithe agus ualach.
____________________________
*        IO L 263, 9.10.2007, lch. 1.".
(2)          Cuirtear an méid seo a leanas in
ionad Airteagal 4(4):
              "Bunóidh an Coimisiún nósanna
imeachta sonracha agus ceanglais shonracha chun mír 2 agus mír 3 den Airteagal
seo a chur chun feidhme. Déanfar na gníomhartha cur chun feidhme sin a ghlacadh
i gcomhréir leis an nós imeachta scrúdúcháin dá dtagraítear in Airteagal 15(2)."
(3)          Cuirtear an méid seo a leanas in
ionad na chéad abairte d'Airteagal 5(3):
              "Tabharfar de chumhacht don
Choimisiún gníomhartha tarmligthe a ghlacadh i gcomhréir le hAirteagal 14a d'fhonn na nósanna imeachta, tástálacha agus ceanglais shonracha is
gá le haghaidh cineál-cheadaithe atá leagtha amach sa mhír seo a fhorbairt, mar
aon leis na ceanglais i ndáil le mír 2 a chur chun feidhme.".
(4)          Cuirtear an méid seo a leanas in
ionad Airteagal 8:
“Airteagal 8
Gníomhartha
tarmligthe maidir le rochtain ar fhaisnéis faoi dheisiú agus faoi chothabháil
feithiclí
Tabharfar de chumhacht
don Choimisiún bearta tarmligthe a ghlacadh, i gcomhréir
le hAirteagal 14a, chun Airteagal 6 agus Airteagal 7 a chur chun
feidhme. Áireofar leis sin sonraíochtaí teicniúla a bhaineann leis an dóigh ina
soláthrófar faisnéis DAB agus faisnéis faoi dheisiú agus faoi chothabháil
feithiclí a shainmhíniú agus a thabhairt cothrom le dáta, agus aird faoi leith
á tabhairt ar riachtanais shonracha FBManna."
(5)          Leasaítear Airteagal 14 mar a
leanas:
(a)     cuirtear an méid seo a leanas in ionad
mhír 1, mhír 2 agus mhír 3:
"1. Gan bhaint de leibhéal na cosanta
comhshaoil laistigh den Aontas, tabharfar de chumhacht don Choimisiún
gníomhartha tarmligthe a ghlacadh i gcomhréir le hAirteagal 14a maidir leis an
méid seo a leanas:
(a)     faisnéis faoi mhais iomlán coibhéisí
astaíochtaí CO2, is é sin suim mhais astaíochtaí CO2 agus
astaíochtaí meatáin, arna sloinneadh i mais choibhéiseach astaíochtaí CO2
i ndáil lena n-éifeachtaí gás ceaptha teasa, a chur in ionad na faisnéise faoi
mhais astaíochtaí CO2 atá sa deimhniú comhréireachta dá dtagraítear
in Airteagal 18 de Threoir 2007/46/CE;

(b)     luach teorann astaíochtaí
lánhidreacarbóin (THC) le haghaidh feithiclí adhainte deimhní.
2. Tar éis Clár Tomhais Cháithnínigh na NA/an ECE,
a reáchtáladh faoi choimirce an Fhóraim Dhomhanda um Chomhfhogasú Rialachán
d'Fheithiclí, a chur i gcrích, agus ar theacht i bhfeidhm Euro 6, ar a dhéanaí,
tabharfar de chumhacht don Choimisiún gníomhartha tarmligthe a ghlacadh i gcomhréir
le hAirteagal 14a chun na bearta seo a leanas a ghlacadh gan bhaint de leibhéal
na cosanta chomhshaoil laistigh den Aontas:
(a)     an Rialachán seo a leasú d'fhonn na
luachanna teorantacha bunaithe ar mhais cháithníneach a leagtar amach in
Iarscríbhinn I a athchalabrú, agus luachanna teorantacha bunaithe ar líon na
gcáithníní a chur isteach san Iarscríbhinn sin ionas go mbeidh siad i
gcomhchoibhneas ginearálta leis na luachanna teorantacha bunaithe ar mhais do
pheitreal agus do dhíosal;
(b)     nós imeachta tomhais leasaithe a ghlacadh
maidir le cáithníní agus luach teorann líon na gcáithníní.
3. Coimeádfaidh an Coimisiún faoi bhreithniú na
nósanna imeachta, tástálacha agus riachtanais dá dtagraítear in Airteagal 5(3)
mar aon leis na sraitheanna tástálacha a úsáidtear chun astaíochtaí a thomhas.
Má shuitear leis an athbhreithniú nach leordhóthanach a thuilleadh na nósanna
imeachta, na tástálacha, na ceanglais agus na sraitheanna tástálacha sin nó
nach léiríonn siad a thuilleadh fíor-astaíochtaí domhanda, gníomhóidh an
Coimisiún i gcomhréir le hAirteagal 5(3) d'fhonn iad a oiriúnú chun go
léireoidh siad go leordhóthanach na hastaíochtaí a ghintear le tiomáint iarbhír
ar an mbóthar."
 (b)    i mír 4, cuirtear isteach an fhomhír
seo a leanas:
"Tabharfar de chumhacht don Choimisiún
gníomhartha tarmligthe a ghlacadh i gcomhréir le hAirteagal 14a chun luach
teorann le haghaidh astaíochtaí NO2 a leagan amach, sa bhreis ar an
luach teorann atá ann cheana i ndáil le hastaíochtaí NOx iomláin, le
haghaidh feithiclí a ceadaíodh a gcomhlíonadh le teorainneacha astaíochta
Euro 6 atá leagtha amach i dtábla 2 d'Iarscríbhinn I. Socrófar an teorainn le haghaidh astaíochtaí NO2 ar bhonn
measúnaithe tionchair, agus cuirfear san áireamh ann an fhéidearthacht
theicniúil agus léireofar inti na cuspóirí maidir le cáilíocht aeir atá leagtha
amach i dTreoir (CE) Uimh. 2008/50 ó Pharlaimint na hEorpa agus ón gComhairle*.
__________________
*           Treoir 2008/50/CE
ó Pharlaimint na hEorpa agus ón gComhairle an 21 Bealtaine 2008 maidir le cáilíocht
an aeir chomhthimpeallaigh agus aer níos glaine don Eoraip (IO L 152,
11.6.2008, lch. 1).
 (c)    cuirtear an méid seo a leanas in ionad
mhír 5:
"5. "Tabharfar de chumhacht don
Choimisiún gníomhartha tarmligthe a ghlacadh i gcomhréir le hAirteagal 14a chun
tábla 4 d'Iarscríbhinn I a leasú agus a fhorlíonadh d'fhonn na teorainneacha a
leagan amach le haghaidh astaíochtaí ó sceithphíopaí ag teochtanna ísle le
haghaidh feithiclí a ceadaíodh a gcomhlíonadh le teorainneacha astaíochta
Euro 6 atá leagtha amach i dtábla 2
d'Iarscríbhinn I. Socrófar an teorainn le haghaidh
astaíochtaí NOx agus NO2 ar bhonn measúnaithe tionchair, agus
cuirfear san áireamh ann an fhéidearthacht theicniúil agus léireofar inti na
cuspóirí maidir le cáilíocht aeir atá leagtha amach i dTreoir (CE) Uimh. 2008/50 ó Pharlaimint na hEorpa agus ón gComhairle."
(6)          Cuirtear Airteagal 14 a
isteach mar a leanas:
"Airteagal 14a
An
tarmligean a fheidhmiú
1.      Is faoi réir na gcoinníollacha
atá leagtha síos san Airteagal seo a thugtar an chumhacht
don Choimisiún gníomhartha tarmligthe a ghlacadh.
2.      Tabharfar an chumhacht don Choimisiún na
gníomhartha tarmligthe dá dtagraítear sa dara fomhír d'Airteagal 2(2), in
Airteagal 5(3), in Airteagal 8 agus in Airteagal 14(1) go (5) a
ghlacadh ar feadh tréimhse neamhchinntithe ón […][Publications Office, please insert the exact date of entry into force].
3.      Féadfaidh Parlaimint na hEorpa nó an
Chomhairle tarmligean na gcumhachtaí dá dtagraítear sa dara fomhír
d'Airteagal 2(2), in Airteagal 5(3), in Airteagal 8 agus in
Airteagal 14(1) go (5) a chúlghairm tráth ar bith. Déanfaidh cinneadh chun
cúlghairm a dhéanamh deireadh a chur le tarmligean na cumhachta atá sonraithe
sa chinneadh sin. Gabhfaidh éifeacht leis an lá tar éis fhoilsiú an chinnidh in
Iris Oifigiúil an Aontais Eorpaigh nó ar dháta is déanaí a shonrófar
ann. Ní dhéanfaidh sé difear do bhailíocht aon cheann de na gníomhartha
tarmligthe atá i bhfeidhm cheana."
4.      A luaithe a ghlacfaidh sé gníomh
tarmligthe, tabharfaidh an Coimisiún fógra ina leith go comhuaineach do
Pharlaimint na hEorpa agus don Chomhairle.
5.      Ní thiocfaidh gníomh tarmligthe a
ghlacfar de bhun an dara fomhír d'Airteagal 2(2), Airteagal 5(3),
Airteagal 8 agus Airteagal 14(1) go (5) i bhfeidhm ach amháin mura
ndéanann Parlaimint na hEorpa nó an Chomhairle agóid ina choinne laistigh de
thréimhse dhá mhí ó fhógra faoin ngníomh sin a thabhairt do Pharlaimint na
hEorpa agus don Chomhairle nó más rud é, sula dtéann an tréimhse sin in éag, go
gcuireann Parlaimint na hEorpa agus an Chomhairle araon in iúl don Choimisiún
nach ndéanfaidh siad agóid ina choinne. Cuirfear dhá mhí leis an tréimhse sin
ar thionscnamh ó Pharlaimint na hEorpa nó ón gComhairle.
(7)        Cuirtear
an méid seo a leanas in ionad Airteagal 15:
"Airteagal 15
An nós imeachta coiste
1.           Beidh coiste de chúnamh ag an
gCoimisiún. Is coiste laistigh de bhrí Rialachán (AE) Uimh. 182/2011 a bheidh sa choiste sin.
2.           I gcás ina ndéanfar tagairt
don mhír seo, beidh feidhm ag Airteagal 5 de Rialachán (AE) Uimh. 182/2011.
I gcás
nach dtugann an coiste tuairim uaidh, ní dhéanfaidh an Coimisiún an
dréachtghníomh cur chun feidhme a ghlacadh agus beidh feidhm ag an tríú fomhír
d'Airteagal 5(4) de Rialachán (AE) Uimh. 182/2011."
Airteagal 2
Leasaítear Rialachán (CE)
Uimh. 595/2009 mar seo a leanas:
(1)          In Airteagal 2, cuirtear an méid seo
a leanas in ionad an dara fomhír:
"Ní bheidh feidhm ag an Rialachán seo maidir
le feithiclí a bhfuil cinneadh déanta ag an déantóir ina leith Rialachán (CE)
Uimh. 715/2007 a chur i bhfeidhm orthu i gcomhréir leis an gcéad fhomhír
d'Airteagal 2(2) den Rialachán sin."
(2)          Sa tábla "Teorainneacha
Astaíochta Euro VI" in Iarscríbhinn I, cuirtear an méid seo a leanas
isteach sa tsraith "WHTC (PI)"
 "WHTC (PI) || 4 000 ||   || 160 || 500 || 460 || - || 10 || ( 3 )".

Airteagal 3
Ní dhéanfaidh an Rialachán difear do nósanna
imeachta atá ar feitheamh faoi Airteagal 5(3),
Airteagal 8 agus Airteagal 14(2)
agus (3) de Rialachán (CE) Uimh. 715/2007 ina bhfuil
a thuairim tugtha cheana féin ag coiste i gcomhréir le hAirteagal 5a de Chinneadh 1999/468/CE.
Airteagal 4
Tiocfaidh an Rialachán seo i bhfeidhm ar an
bhfichiú lá tar éis a fhoilsithe in Iris Oifigiúil an Aontais Eorpaigh.
Beidh
an Rialachán seo ina cheangal go huile agus go hiomlán agus beidh sé infheidhme
go díreach i ngach Ballstát.
Arna dhéanamh sa Bhruiséil,
Thar ceann Pharlaimint na hEorpa               Thar
ceann na Comhairle
An tUachtarán                                               An
tUachtarán
[1]               IO C , , p. .
[2]               IO C 182, 19.7.2008, lch. 17.
[3]               Rialachán (CE) Uimh. 715/2007 ó Pharlaimint na hEorpa
agus ón gComhairle an 20 Meitheamh 2007 maidir le cineál-cheadú mótarfheithiclí
i dtaca le hastaíochtaí ó fheithiclí éadroma paisinéirí agus tráchtála (Euro 5
agus Euro 6) agus maidir le rochtain ar fhaisnéis faoi dheisiú agus faoi
chothabháil feithiclí (IO L 171, 29.6.2007, p. 1).
[4]               Treoir 98/69/CE ó Pharlaimint na hEorpa agus ón
gComhairle an 13 Deireadh Fómhair 1998 maidir le bearta atá le glacadh i
gcoinne thruailliú an aeir ag astaíochtaí mótarfheithiclí agus lena leasaítear
Treoir 70/220/IO (IO L 350, 28.12.1998, lch. 1).
[5]               Rialachán (CE) Uimh. 595/2009 ó Pharlaimint na hEorpa
agus ón gComhairle an 18 Meitheamh 2009 maidir le mótarfheithiclí agus innill a
chineál-cheadú i leith astaíochtaí ó fheithiclí saothair throm (Euro VI) agus
maidir le rochtain ar fhaisnéis faoi fheithiclí a dheisiú agus a chothabháil
agus lena leasaítear Rialachán (CE) Uimh. 715/2007 agus Treoir 2007/46/CE agus
lena n-aisghairtear Treoir 80/1269/CEE, Treoir 2005/55/CE agus Treoir
2005/78/CE (IO L 188, 18.7.2009, p. 1).
[6]               Cinneadh 1999/468/CE ón gComhairle an 28 Meitheamh 1999
lena leagtar síos na nósanna imeachta maidir le feidhmiú na gcumhachtaí cur
chun feidhme arna dtabhairt don Choimisiún (IO L 184, 17.7.1999, lch. 23).
[7]               Rialachán (AE) Uimh. 182/2011 ó Pharlaimint na
hEorpa agus ón gComhairle an 16 Feabhra 2011 lena leagtar síos na rialacha agus
na prionsabail ghinearálta a bhaineann leis na sásraí maidir le rialú ag na
Ballstáit ar fheidhmiú cumhachtaí cur chun feidhme ag an gCoimisiún,
(IO L 55, 28.2.2011, lch. 13.


|

52010PC0397

Togra le haghaidh RIALACHÁIN Ó PHARLAIMINT NA hEORPA AGUS ÓN gCOMHAIRLE lena ndéantar foráil chun déileáil ar bhonn saor ó dhleacht le comhábhair shonraithe ghníomhacha chógaisíochta ar a bhfuil "ainm neamhdhílseánaigh idirnáisiúnta (ANI)" ón Eagraíocht Dhomhanda Sláinte agus le táirgí sonraithe a úsáidtear chun cógais chríochnaithe a mhonarú agus lena leasaítear Iarscríbhinn I a ghabhann le Rialachán (CEE) Uimh. 2658/87  /* COM /2010/0397 final COD 2010/0214 */

	[pic] | AN COIMISIÚN EORPACH |An Bhruiséil 27.7.2010COIM(2010)397 leagan deireanach2010/0214 (COD)Togra le haghaidhRIALACHÁIN Ó PHARLAIMINT NA hEORPA AGUS ÓN gCOMHAIRLElena ndéantar foráil chun déileáil ar bhonn saor ó dhleacht le comhábhair shonraithe ghníomhacha chógaisíochta ar a bhfuil "ainm neamhdhílseánaigh idirnáisiúnta (ANI)" ón Eagraíocht Dhomhanda Sláinte agus le táirgí sonraithe a úsáidtear chun cógais chríochnaithe a mhonarú agus lena leasaítear Iarscríbhinn I a ghabhann le Rialachán (CEE) Uimh. 2658/87MEABHRÁN MÍNIÚCHÁINIs é atá sa Taifead ar an bPlé faoi Thrádáil i dTáirgí Cógaisíochta socrú idir na tíortha is mó a tháirgeann cógais chun na dualgais a cheanglaíonn an Eagraíocht Dhomhanda Trádála (EDT) orthu maidir le dleachtanna a laghdú go náid, agus é sin a dhéanamh ar bhonn an Náisiúin Bharrfhabhair (MFN), ar dleachtanna iad ar tháirgí cógaisíochta áirithe, lena n-áirítear comhábhair ghníomhacha agus táirgí idirmheánacha. Is iad na Páirtithe sa Chomhaontú sin an AE, Stáit Aontaithe Mheiriceá, an tSeapáin, Ceanada, an Eilvéis, an Iorua agus Macao (an tSín).I dtosach, chuimsigh an socrú níos mó ná sé mhíle táirge. Ós rud é, áfach, go bhfuil táirgí nua cógaisaíochta á bhforbairt an t-am ar fad, déantar foráil sa socrú d'athbhreithnithe tráthrialta. D'aontaigh na Páirtithe "go mbuailfeadh siad le chéile faoi choimirce Chomhairle um Thrádáil Earraí an EDT, ar a laghad uair gach trí bliana, chun athbhreithniú a dhéanamh ar chuimsiú na dtáirgí d'fhonn táirgí breise cógaisíochta a chur san áireamh, trí chomhthoil, do scrios na taraife." Rinneadh athbhreithniú ar an gcuimsiú den chéad uair i 1995-1996 agus, dá thoradh sin, rinneadh an cinneadh déileáil le 465 táirge breise ar bhonn saor ó dhleacht. Mar thoradh ar an dara hathbhreithniú i 1998 (arna chur chun feidhme i mí Iúil 1999) déileáladh le 639 táirge breise ar bhonn saor ó dhleacht. Mar thoradh ar an tríú hathbhreithniú in 2006 cuireadh 1290 táirgí leis an méid sin.Leis an togra seo, iarrtar ar an gComhairle agus ar an bParlaimint cead a thabhairt 718 táirge cógaisíochta agus ceimiceach a chur leis an liosta atá ann cheana ar a bhfuil 8619 táirge, a bhfuil ceangal ann déileáil leo ar bhonn saor ó dhleacht, nuair a allmhairítear san AE iad.In 2009, cuireadh tús leis an gceathrú hathbhreithniú ar na táirgí atá cuimsithe sa Taifead, i gcomhréir le hAirteagal 3 den Taifead, Airteagal lena gcuirtear de cheangal ar Rannpháirtithe athbhreithniú a dhéanamh, ar a laghad uair gach trí bliana, ar chuimsiú na dtáirgí d'fhonn táirgí breise cógaisaíochta a chur san áireamh do scrios na taraife. Ghlac an AE páirt sa phlé teicniúil sin. Le linn an phlé sin, tháinig Rannpháirtithe ar an gconclúid, maidir le ANInna breise agus le táirgí idirmheánacha cógaisíochta a úsáidtear chun cógais chríochnaithe a tháirgeadh agus a mhonarú, gur cheart déileáil leo ar bhonn saor ó dhleacht agus maidir le liosta na réimíreanna agus na n-iarmhíreanna sonraithe le haghaidh salann, eistear nó hiodráití d'ANInna, gur cheart cur leis, sa chaoi sin ag cur 718 substaint nua le liosta na dtáirgí ar féidir déileáil leo ar bhonn saor ó dhleacht.Chuathas i gcomhairle leis na Ballstáit le linn an phlé theicniúil.Iarrtar ar an gComhairle agus ar an bParlaimint an togra a ghabhann leis seo a ghlacadh, is é sin an togra le haghaidh Rialacháin ó Pharlaimint na hEorpa agus ón gComhairle lena leasaítear Iarscríbhinn I a ghabhann le Rialachán (CEE) Uimh. 2658/87 maidir le síneadh ar dhéileáil leis na táirgí cógaisíochta agus ceimiceacha thuasluaite ar bhonn saor ó dhleacht san Aontas Eorpach.2010/0214 (COD)Togra le haghaidhRIALACHÁIN Ó PHARLAIMINT NA hEORPA AGUS ÓN gCOMHAIRLElena ndéantar foráil chun déileáil ar bhonn saor ó dhleacht le comhábhair shonraithe ghníomhacha chógaisíochta ar a bhfuil "ainm neamhdhílseánaigh idirnáisiúnta (ANI)" ón Eagraíocht Dhomhanda Sláinte, agus le táirgí sonraithe a úsáidtear chun cógais chríochnaithe a mhonarú agus lena leasaítear Iarscríbhinn I a ghabhann le Rialachán (CEE) Uimh. 2658/87TÁ PARLAIMINT NA HEORPA AGUS COMHAIRLE AN AONTAIS EORPAIGH,Ag féachaint don Chonradh ar Fheidhmiú an Aontais Eorpaigh, agus go háirithe Airteagal 207 de,Ag féachaint don togra ón gCoimisiún Eorpach,Tar éis dóibh an dréachtghníomh reachtach a chur chuig na Parlaimintí náisiúnta,Ag gníomhú dóibh i gcomhréir leis an ngnáthnós imeachta reachtach,De bharr an méid seo a leanas:(1) Le linn na caibidlíochta a bhain le Babhta Uragua, d'aontaigh an Comhphobal agus roinnt tíortha gur cheart déileáil ar bhonn saor ó dhleacht le táirgí cógaisíochta a thagann faoi Chaibidil 30 den Chóras Comhchuibhithe (CC) agus faoi cheannteidil CC 2936, 2937, 2939 agus 2941, mar aon le comhábhair shonraithe ghníomhacha chógaisíochta ar a bhfuil "ainm neamhdhílseánaigh idirnáisiúnta (ANI)" ón Eagraíocht Dhomhanda Sláinte (EDT), le salainn shonraithe, eistir shonraithe nó hiodráití sonraithe na nANInna sin, agus le táirgí sonraithe idirmheánacha cógaisíochta a úsáidtear chun cógais chríochnaithe a tháirgeadh agus a mhonarú.(2) Ionchorpraíodh torthaí an phlé sin, mar a leagadh amach iad i dtaifead an phlé, i sceidil taraifí na rannpháirtithe a cuireadh i gceangal le Prótacal Marrakech a ghabhann leis an gComhaontú Ginearálta um Tharaifí agus Trádáil 1994.(3) D'aontaigh na Páirtithe go mbuailfeadh ionadaithe chomhaltaí an EDT le chéile faoi choimirce Chomhairle um Thrádáil Earraí an EDT, ar a laghad uair gach trí bliana, chun cuimsiú na dtáirgí a athbhreithniú d'fhonn táirgí breise cógaisíochta a chur san áireamh, trí chomhthoil, do scrios na taraife. Is páirtithe iad comhaltaí an EDT i dtaifead an phlé.(4) Mar thoradh ar thrí athbhreithniú atáthar tar éis a dhéanamh, déileáiltear ar bhonn saor ó dhleacht le líon áirithe ANInna breise agus le líon áirithe táirgí idirmheánacha cógaisíochta a úsáidtear chun cógais chríochnaithe a tháirgeadh agus a mhonarú, táthar tar éis táirgí áirithe as measc na dtáirgí idirmheánacha sin a aistriú go liosta na n-ANInna, agus táthar tar éis cur le liosta na réimíreanna agus na n-iarmhíreanna sonraithe le haghaidh salann, eistear nó hiodráití d'ANInna.(5) Measadh gurbh iomchuí an ceathrú hathbhreithniú a dhéanamh agus cuireadh tús leis an athbhreithniú sin in 2009. Baineadh de thátal as gur cheart déileáil ar bhonn saor ó dhleacht le líon áirithe ANInna breise agus le líon áirithe táirgí idirmheánacha cógaisíochta a úsáidtear chun cógais chríochnaithe a tháirgeadh agus a mhonarú, gur cheart táirgí áirithe de na táirgí idirmheánacha a áiríodh cheana a aistriú go liosta na n-ANInna, agus gur cheart cur le liosta na réimíreanna agus na n-iarmhíreanna sonraithe le haghaidh salann, eistear nó hiodráití d'ANInna.(6) Le Rialachán (CEE) ón gComhairle Uimh. 2658/87 an 23 Iúil 1987 maidir leis an ainmníocht taraife agus staidrimh agus leis an gComhtharaif Chustaim[1] bunaíodh an Ainmníocht Chomhcheangailte (AC) agus leagadh amach rátaí dleachta coinbhinsiúnta na Comhthairife Custaim.(7) Dá bhrí sin, ba chóir Rialachán (CEE) Uimh. 2658/87 a leasú dá réir sin.(8) (Ionas go n-áiritheofar go mbeidh na bearta dá bhforáiltear sa Rialachán seo i bhfeidhm ar an 1 Eanáir 2011, ba cheart go dtiocfadh sé i bhfeidhm an lá tar éis lá a fhoilsithe.]TAR ÉIS AN RIALACHÁN SEO A GHLACADH:Airteagal 1Ón 1 Eanáir 2011 i leith déileálfaidh an tAontas Eorpach ar bhonn saor ó dhleacht leis na ANInna a liostaítear in Iarscríbhinn I.Airteagal 2Ón 1 Eanáir 2011, maidir le liosta na réimíreanna agus na n-iarmhíreanna lena dtuairiscítear, i gcomhcheangal leis na ANInna atá ar áireamh, salainn, eistir nó hiodráití d'ANInna ar féidir déileáil leo freisin ar bhonn saor ó dhleacht, ar choinníoll gur féidir iad a aicmiú faoin bhfo-cheannteideal CC sé dhigit céanna leis an ANI comhfhreagrach, déanfar an liosta a leasú mar a leagtar amach in Iarscríbhinn II.Airteagal 3Ón 1 Eanáir 2011 déileálfaidh an tAontas Eorpach ar bhonn saor ó dhleacht freisin leis na táirgí idirmheánacha cógaisíochta a úsáidtear chun cógais chríochnaithe a tháirgeadh agus a mhonarú agus a liostaítear in Iarscríbhinn III.Airteagal 4Ón 1 Eanáir 2011 déanfar na táirgí idirmheánacha cógaisíochta a liostaítear in Iarscríbhinn IV a bhaint ó liosta na gcomhdhúl sin a ndéileáiltear leo ar bhonn saor ó dhleacht.Airteagal 5Déanfar Iarscríbhinní 3, 4 agus 6 de Roinn II de Chuid a trí d'Iarscríbhinn I a ghabhann le Rialachán (CEE) Uimh. 2658/87 (Liostaí substaintí cógaisíochta ar féidir déileáil leo ar bhonn saor ó dhleacht), a leasú dá réir.Airteagal 6Tiocfaidh an Rialachán seo i bhfeidhm an lá tar éis lá a fhoilsithe in Iris Oifigiúil an Aontais Eorpaigh.Beidh an Rialachán seo ina cheangal go huile agus go hiomlán agus beidh sé infheidhme go díreach i ngach Ballstát.Arna dhéanamh sa Bhruiséil, an […]Thar ceann Pharlaimint na hEorpa Thar ceann na ComhairleAn tUachtarán An tUachtarán […] […]IARSCRÍBHINN ILiosta ainmneacha neamhdhílseánacha idirnáisiúnta (ANInna) le cur le liosta na dtáirgí a ndéileáiltear leo ar bhonn saor ó dhleacht agus atá ar áireamh in Iarscríbhinn 3 d'Iarscríbhinn I a ghabhann le Rialachán (CEE) Uimh. 2658/87Cód AC | Uimh. CAS RN | Ainm |2842 90 80 | 119175-48-3 | fermagate |2843 90 90 | 759457-82-4 | padeliporfin |2844 40 30 | 123748-56-1 | iodofiltic acid (123I) |2904 10 00 | 21668-77-9 | eprodisate |2906 19 00 | 199798-84-0 | elocalcitol |2909 30 90 | 24150-24-1 | terameprocol |2916 19 95 | 81485-25-8 | peretinoin |2916 39 00 | 51543-40-9 | tarenflurbil |2918 19 98 | 174022-42-5 | bevirimat |2919 90 00 | 258516-89-1 | fospropofol |2920 90 85 | 163133-43-5 | naproxcinod |2921 19 99 | 3687-18-1 | tramiprosate |2922 19 85 | 68392-35-8 | afimoxifene |2922 19 85 | 753449-67-1 | ronacaleret |2922 29 00 | 433265-65-7 | faxeladol |2922 50 00 | 121524-08-1 | Amibegron |2922 50 00 | 329773-35-5 | Cinaciguat |2922 50 00 | 643094-49-9 | fasobegron |2923 10 00 | 856676-23-8 | choline fenofibrate |2924 29 98 | 847353-30-4 | arbaclofen placarbil |2924 29 98 | 194785-19-8 | bedoradrine |2924 29 98 | 194085-75-1 | Carisbamate |2924 29 98 | 254750-02-2 | emricasan |2924 29 98 | 355129-15-6 | eprotirome |2924 29 98 | 402567-16-2 | firategrast |2924 29 98 | 478296-72-9 | gabapentin enacarbil |2924 29 98 | 15866-90-7 | incyclinide |2924 29 98 | 202844-10-8 | indantadol |2924 29 98 | 96847-55-1 | levomilnacipran |2924 29 98 | 608137-32-2 | lisdexamfetamine |2924 29 98 | 652990-07-3 | milveterol |2924 29 98 | 181816-48-8 | ombrabulin |2924 29 98 | 289656-45-7 | senicapoc |2925 19 95 | 19171-19-8 | pomalidomide |2928 00 90 | 22033-87-0 | olesoxime |2928 00 90 | 2675-35-6 | sivifene |2928 00 90 | 816458-31-8 | tecovirimat |2928 00 90 | 238750-77-1 | tosedostat |2928 00 90 | 149647-78-9 | vorinostat |2929 90 00 | 31645-39-3 | palifosfamide |2930 90 99 | 608141-41-9 | apremilast |2930 90 99 | 216167-92-9 | camobucol |2930 90 99 | 211513-37-0 | dalcetrapib |2930 90 99 | 69819-86-9 | Darinaparsin |2930 90 99 | 488832-69-5 | elesclomol |2930 90 99 | 216167-95-2 | elsibucol |2930 90 99 | 168682-53-9 | ezatiostat |2930 90 99 | 58569-55-4 | metenkefalin |2930 90 99 | 887148-69-8 | Monepantel |2930 90 99 | 603139-19-1 | odanacatib |2930 90 99 | 162520-00-5 | salirasib |2930 90 99 | 216167-82-7 | succinobucol |2930 90 99 | 125961-82-2 | tipelukast |2931 00 99 | 125973-56-0 | amsilarotene |2932 19 00 | 253128-41-5 | eribulin |2932 19 00 | 186953-56-0 | pafuramidine |2932 29 85 | 195883-06-8 | Omtriptolide |2932 99 00 | 664338-39-0 | arterolane |2932 99 00 | 183133-96-2 | cabazitaxel |2932 99 00 | 401925-43-7 | celivarone |2932 99 00 | 461432-26-8 | dapagliflozin |2932 99 00 | 118457-15-1 | dexnebivolol |2932 99 00 | 156294-36-9 | larotaxel |2932 99 00 | 118457-16-2 | levonebivolol |2932 99 00 | 83461-56-7 | Mifamurtide |2932 99 00 | 117570-53-3 | vadimezan |2933 19 90 | 496775-61-2 | eltrombopag |2933 19 90 | 206884-98-2 | niraxostat |2933 19 90 | 410528-02-8 | palovarotene |2933 19 90 | 376592-42-6 | totrombopag |2933 29 90 | 183659-72-5 | catramilast |2933 29 90 | 944263-65-4 | demiditraz |2933 29 90 | 867153-61-5 | dulanermin |2933 29 90 | 320367-13-3 | lixisenatide |2933 29 90 | 698389-00-3 | rolipoltide |2933 29 90 | 697766-75-9 | velafermin |2933 39 99 | 147084-10-4 | alcaftadine |2933 39 99 | 54-96-6 | Amifampridine |2933 39 99 | 249921-19-5 | anamorelin |2933 39 99 | 319460-85-0 | axitinib |2933 39 99 | 208110-64-9 | befiradol |2933 39 99 | 330942-05-7 | betrixaban |2933 39 99 | 201034-75-5 | daporinad |2933 39 99 | 209783-80-2 | entinostat |2933 39 99 | 412950-27-7 | goxalapladib |2933 39 99 | 218791-21-0 | imisopasem manganese |2933 39 99 | 103129-82-4 | levamlodipine |2933 39 99 | 154357-42-3 | levonadifloxacin |2933 39 99 | 108147-54-2 | migalastat |2933 39 99 | 453562-69-1 | motesanib |2933 39 99 | 139145-27-0 | parogrelil |2933 39 99 | 459856-18-9 | pexacerfont |2933 39 99 | 706779-91-1 | pimavanserin |2933 39 99 | 362665-56-3 | Pitolisant |2933 39 99 | 861151-12-4 | rosonabant |2933 39 99 | 701977-09-5 | taranabant |2933 39 99 | 189950-11-6 | tropantiol |2933 39 99 | 793655-64-8 | Vapitadine |2933 39 99 | 139290-65-6 | volinaserin |2933 49 90 | 141388-76-3 | besifloxacin |2933 49 90 | 697761-98-1 | elvitegravir |2933 49 90 | 185055-67-8 | ferroquine |2933 49 90 | 445041-75-8 | intiquinatine |2933 49 90 | 378746-64-6 | nemonoxacin |2933 49 90 | 245765-41-7 | ozenoxacin |2933 49 90 | 412950-08-4 | rilapladib |2933 49 90 | 871224-64-5 | almorexant |2933 49 90 | 863029-99-6 | balamapimod |2933 49 90 | 698387-09-6 | neratinib |2933 49 90 | 154652-83-2 | tezampanel |2933 49 90 | 128253-31-6 | veliflapon |2933 59 95 | 791828-58-5 | aderbasib |2933 59 95 | 840486-93-3 | Adipiplon |2933 59 95 | 850649-61-5 | Alogliptin |2933 59 95 | 859212-16-1 | Bafetinib |2933 59 95 | 380843-75-4 | Bosutinib |2933 59 95 | 839712-12-8 | cariprazine |2933 59 95 | 414910-27-3 | casopitant |2933 59 95 | 288383-20-0 | cediranib |2933 59 95 | 849550-05-6 | cevipabulin |2933 59 95 | 827318-97-8 | danusertib |2933 59 95 | 356057-34-6 | darapladib |2933 59 95 | 501000-36-8 | dutacatib |2933 59 95 | 247257-48-3 | fimasartan |2933 59 95 | 3432-99-3 | folitixorin |2933 59 95 | 668270-12-0 | linagliptin |2933 59 95 | 441798-33-0 | macitentan |2933 59 95 | 641571-10-0 | Nilotinib |2933 59 95 | 763113-22-0 | Olaparib |2933 59 95 | 686344-29-6 | otenabant |2933 59 95 | 625115-55-1 | riociguat |2933 59 95 | 486460-32-6 | sitagliptin |2933 59 95 | 425637-18-9 | sotrastaurin |2933 59 95 | 309913-83-5 | talmapimod |2933 59 95 | 113857-87-7 | talotrexin |2933 59 95 | 274693-27-5 | ticagrelor |2933 59 95 | 306296-47-9 | vicriviroc |2933 69 80 | 775351-65-0 | imeglimin |2933 79 00 | 461443-59-4 | aplaviroc |2933 79 00 | 189691-06-3 | bremelanotide |2933 79 00 | 813452-18-5 | carmegliptin |2933 79 00 | 405169-16-6 | dovitinib |2933 79 00 | 536748-46-6 | eribaxaban |2933 79 00 | 473289-62-2 | ilepatril |2933 79 00 | 180694-97-7 | mimopezil |2933 79 00 | 579475-18-6 | orvepitant |2933 79 00 | 449811-01-2 | pamapimod |2933 79 00 | 248282-01-1 | paquinimod |2933 79 00 | 380917-97-5 | perampanel |2933 79 00 | 552292-08-7 | rolapitant |2933 79 00 | 425386-60-3 | semagacestat |2933 79 00 | 515814-01-4 | voclosporin |2933 99 80 | 481629-87-2 | aleplasinin |2933 99 80 | 394730-60-0 | boceprevir |2933 99 80 | 649735-63-7 | brivanib alaninate |2933 99 80 | 483369-58-0 | denagliptin |2933 99 80 | 284019-34-7 | denibulin |2933 99 80 | 481631-45-2 | diaplasinin |2933 99 80 | 272105-42-7 | disitertide |2933 99 80 | 227318-71-0 | epetirimod |2933 99 80 | 259793-96-9 | favipiravir |2933 99 80 | 871576-03-3 | flovagatran |2933 99 80 | 229305-39-9 | golotimod |2933 99 80 | 258818-34-7 | larazotide |2933 99 80 | 571170-77-9 | laropiprant |2933 99 80 | 616202-92-7 | lorcaserin |2933 99 80 | 868771-57-7 | melogliptin |2933 99 80 | 803712-67-6 | obatoclax |2933 99 80 | 404950-80-7 | panobinostat |2933 99 80 | 625114-41-2 | piragliatin |2933 99 80 | 74847-35-1 | pyronaridine |2933 99 80 | 872178-65-9 | rabeximod |2933 99 80 | 355151-12-1 | rotigaptide |2933 99 80 | 497221-38-2 | rusalatide |2933 99 80 | 187602-11-5 | sofigatran |2933 99 80 | 227318-75-4 | sotirimod |2933 99 80 | 402957-28-2 | telaprevir |2933 99 80 | 848084-83-3 | tigapotide |2933 99 80 | 393105-53-8 | tiplasinin |2933 99 80 | 620948-93-8 | vabicaserin |2933 99 80 | 794466-70-9 | vernakalant |2934 10 00 | 544417-40-5 | Capadenoson |2934 10 00 | 302962-49-8 | dasatinib |2934 10 00 | 223132-37-4 | inolitazone |2934 10 00 | 241479-67-4 | isavuconazole |2934 10 00 | 338990-84-4 | isavuconazonium chloride |2934 10 00 | 607723-33-1 | lobeglitazone |2934 10 00 | 280782-97-0 | managlinat dialanetil |2934 10 00 | 790299-79-5 | masitinib |2934 10 00 | 223673-61-8 | mirabegron |2934 10 00 | 501948-05-6 | rosabulin |2934 10 00 | 447406-78-2 | sodelglitazar |2934 10 00 | 760937-92-6 | teneligliptin |2934 20 80 | 848344-36-5 | Bentamapimod |2934 20 80 | 870093-23-5 | talarozole |2934 99 90 | 320345-99-1 | aclidinium bromide |2934 99 90 | 222551-17-9 | adoprazine |2934 99 90 | 207623-20-9 | agatolimod |2934 99 90 | 475479-34-6 | aleglitazar |2934 99 90 | 870524-46-2 | amolimogene bepiplasmid |2934 99 90 | 875446-37-0 | anacetrapib |2934 99 90 | 250386-15-3 | apadenoson |2934 99 90 | 541550-19-0 | apilimod |2934 99 90 | 160707-69-7 | apricitabine |2934 99 90 | 147403-03-0 | azilsartan |2934 99 90 | 863031-21-4 | azilsartan medoxomil |2934 99 90 | 757942-43-1 | bederocin |2934 99 90 | 627861-07-8 | beperminogene perplasmid |2934 99 90 | 959961-96-7 | bevasiranib |2934 99 90 | 769901-96-4 | capeserod |2934 99 90 | 868540-17-4 | carfilzomib |2934 99 90 | 872847-66-0 | cenersen |2934 99 90 | 80295-38-1 | conestat alfa |2934 99 90 | 903916-27-8 | custirsen |2934 99 90 | 187865-22-1 | derquantel |2934 99 90 | 134379-77-4 | dexelvucitabine |2934 99 90 | 247046-52-2 | dilopetine |2934 99 90 | 480449-70-5 | edoxaban |2934 99 90 | 188181-42-2 | elacytarabine |2934 99 90 | 98819-76-2 | esreboxetine |2934 99 90 | 763903-67-9 | fosalvudine tidoxil |2934 99 90 | 172673-20-0 | fosaprepitant |2934 99 90 | 522664-63-7 | ibodutant |2934 99 90 | 405159-59-3 | idrabiotaparinux sodium |2934 99 90 | 188116-07-6 | imepitoin |2934 99 90 | 335619-18-6 | inakalant |2934 99 90 | 1391-36-2 | lancovutide |2934 99 90 | 189059-71-0 | lapaquistat |2934 99 90 | 327026-93-7 | lensiprazine |2934 99 90 | 170632-47-0 | lificiguat |2934 99 90 | 852313-25-8 | litenimod |2934 99 90 | 1000120-98-8 | mipomersen |2934 99 90 | 62253-63-8 | nepidermin |2934 99 90 | 26833-87-4 | omacetaxine mepesuccinate |2934 99 90 | 269718-84-5 | pardoprunox |2934 99 90 | 219923-85-0 | Pramiconazole |2934 99 90 | 377727-87-2 | preladenant |2934 99 90 | 524684-52-4 | prinaberel |2934 99 90 | 865311-47-3 | quarfloxin |2934 99 90 | 869884-78-6 | radezolid |2934 99 90 | 496054-87-6 | radiprodil |2934 99 90 | 518048-05-0 | raltegravir |2934 99 90 | 787548-03-2 | regrelor |2934 99 90 | 820957-38-8 | Retosiban |2934 99 90 | 572924-54-0 | Ridaforolimus |2934 99 90 | 128517-07-7 | romidepsin |2934 99 90 | 93265-81-7 | Ropidoxuridine |2934 99 90 | 151823-14-2 | sapacitabine |2934 99 90 | 379231-04-6 | saracatinib |2934 99 90 | 791635-59-1 | simotaxel |2934 99 90 | 119567-79-2 | taribavirin |2934 99 90 | 332012-40-5 | telatinib |2934 99 90 | 925681-61-4 | trabedersen |2934 99 90 | 189003-92-7 | trelanserin |2934 99 90 | 296251-72-4 | velimogene aliplasmid |2934 99 90 | 904302-98-3 | viquidacin |2934 99 90 | 872525-61-6 | votucalis |2934 99 90 | 221877-54-9 | zotarolimus |2935 00 90 | 197904-84-0 | apricoxib |2935 00 90 | 769169-27-9 | begacestat |2935 00 90 | 414864-00-9 | belinostat |2935 00 90 | 313682-08-5 | brecanavir |2935 00 90 | 839673-52-8 | cevoglitazar |2935 00 90 | 358970-97-5 | drinabant |2935 00 90 | 865200-20-0 | giripladib |2935 00 90 | 464213-10-3 | ibipinabant |2935 00 90 | 173424-77-6 | laromustine |2935 00 90 | 398507-55-6 | lodenafil carbonate |2935 00 90 | 136564-68-6 | masilukast |2935 00 90 | 170569-88-7 | mavacoxib |2935 00 90 | 862189-95-5 | mirodenafil |2935 00 90 | 439687-69-1 | nelivaptan |2935 00 90 | 691852-58-1 | nesbuvir |2935 00 90 | 778576-62-8 | oglemilast |2935 00 90 | 444731-52-6 | pazopanib |2935 00 90 | 362505-84-8 | relacatib |2935 00 90 | 243984-11-4 | resatorvid |2935 00 90 | 519055-62-0 | tasisulam |2935 00 90 | 186497-07-4 | zibotentan |2936 29 00 | 104121-92-8 | Eldecalcitol |2936 29 00 | 31690-09-2 | levomefolic acid |2937 19 00 | 782500-75-8 | albiglutide |2937 19 00 | 348119-84-6 | obinepitide |2937 19 00 | 295350-45-7 | ozarelix |2937 19 00 | 275371-94-3 | taspoglutide |2937 19 00 | 218949-48-5 | tesamorelin |2937 19 00 | 22006-64-0 | tridecactide |2937 22 00 | 132245-57-9 | dexamethasone cipecilate |2937 22 00 | 397864-44-7 | fluticasone furoate |2937 29 00 | 211254-73-8 | Lonaprisan |2937 50 00 | 333963-42-1 | cobiprostone |2937 50 00 | 172740-14-6 | posaraprost |2937 90 00 | 834153-87-6 | elagolix |2937 90 00 | 609799-22-6 | tasimelteon |2937 90 00 | 342577-38-2 | velneperit |2939 19 00 | 73232-52-7 | methylnaltrexone bromide |2939 59 00 | 136199-02-5 | rolofylline |2939 99 00 | 850607-58-8 | darotropium bromide |2939 99 00 | 187852-63-7 | Delimotecan |2940 00 00 | 9007-72-1 | ferric carboxymaltose |2940 00 00 | 442201-24-3 | remogliflozin etabonate |2940 00 00 | 408504-26-7 | sergliflozin etabonate |2941 90 00 | 467214-20-6 | Alvespimycin |2941 90 00 | 677017-23-1 | Berubicin |2941 90 00 | 229016-73-3 | ceftaroline fosamil |2941 90 00 | 318498-76-9 | flopristin |2941 90 00 | 145435-72-9 | Gamithromycin |2941 90 00 | 325965-23-9 | linopristin |2941 90 00 | 857402-23-4 | retaspimycin |2941 90 00 | 305841-29-6 | sagopilone |2941 90 00 | 75747-14-7 | Tanespimycin |2941 90 00 | 328898-40-4 | tildipirosin |2941 90 00 | 222400-20-6 | tomopenem |2941 90 00 | 63409-12-1 | tylvalosin |3001 90 91 | 9041-08-1 | semuloparin sodium |3002 10 91 | 792921-10-9 | abagovomab |3002 10 91 | 910649-32-0 | anrukinzumab |3002 10 91 | 648904-28-3 | bavituximab |3002 10 91 | 402710-27-4 (light chain) 402710-25-2 (heavy chain) | canakinumab |3002 10 99 | 945228-49-9 | citatuzumab bogatox |3002 10 91 | 880486-59-9 | dacetuzumab |3002 10 91 | 615258-40-7 | denosumab |3002 10 91 | 762260-74-2 | efungumab |3002 10 91 | 89957-37-9 | gantenerumab |3002 10 91 | 680188-33-4 | ibalizumab |3002 10 91 | 477202-00-9 | ipilimumab |3002 10 91 | 640735-09-7 | iratumumab |3002 10 91 | 845816-02-6 | lexatumumab |3002 10 91 | 903512-50-5 | lucatumumab |3002 10 91 | 899796-83-9 | milatuzumab |3002 10 91 | 677010-34-3 | motavizumab |3002 10 91 | 676258-98-3 | naptumomab estafenatox |3002 10 91 | 828933-51-3 | nimotuzumab |3002 10 91 | 949142-50-1 | Obinutuzumab |3002 10 91 | 637334-45-3 | ocrelizumab |3002 10 91 | 881191-44-2 | otelixizumab |3002 10 91 | 372075-37-1 | sontuzumab |3002 10 91 | 705287-60-1 | stamulumab |3002 10 91 | 339086-80-5 | tadocizumab |3002 10 91 | 592557-43-2 (light chain) 592557-41-0 (heavy chain) | Tenatumomab |3002 10 91 | 876387-05-2 | teplizumab |3002 10 91 | 918127-53-4 | tigatuzumab |3002 10 91 | 745013-59-6 | Tremelimumab |3002 10 91 | 339986-90-2 | tucotuzumab celmoleukin |3002 10 91 | 728917-18-8 | veltuzumab |3002 10 91 | 896731-82-1 | conatumumab |3002 10 91 | 892553-42-3 | etaracizumab |3002 10 91 | 944548-38-3 | foravirumab |3002 10 91 | 944548-37-2 | rafivirumab |3002 10 91 | 880266-57-9 | tanezumab |3002 10 91 | 815610-63-0 | ustekinumab |3002 10 95 | 862111-32-8 | aflibercept |3002 10 95 | 845264-92-8 | atacicept |3002 10 95 | 909110-25-4 | baminercept |3002 10 95 | 9001-27-8 | beroctocog alfa |3002 10 95 | 879555-13-2 | epoetin kappa |3002 10 95 | 762263-14-9 | epoetin theta |3002 10 95 | 501081-76-1 | rilonacept |3002 10 95 | 267639-76-9 | romiplostim |3002 10 95 | 869858-13-9 | thrombin alfa |3002 10 95 | 897936-89-9 | vatreptacog alfa (activated) |3002 10 95 | 472960-22-8 | albinterferon alfa-2b |3002 10 95 | 869881-54-9 | briobacept |3002 10 95 | 606138-08-3 | catridecacog |3002 10 95 | 716840-32-3 | denenicokin |3002 10 95 | 931101-84-7 | troplasminogen alfa |3002 10 99 | 934216-54-3 | alacizumab pegol |3002 20 00 | 181477-43-0 | disomotide |3002 20 00 | 181477-91-8 | ovemotide |3002 20 00 | 915019-08-8 | tertomotide |3002 20 00 | 295371-00-5 | verpasep caltespen |3002 90 90 | 473553-86-5 | Alferminogene tadenovec |3002 90 90 | 929881-05-0 | alipogene tiparvovec |3002 90 90 | 600735-73-7 | contusugene ladenovec |3002 90 90 | 851199-59-2 | Linaclotide |3002 90 90 | 898830-54-1 | sitimagene ceradenovec |3002 90 90 | 721946-42-5 | transferrin aldifitox |3507 90 90 | 9026-00-0 | bucelipase alfa |3507 90 90 | 885051-90-1 | pegloticase |3507 90 90 | 884604-91-5 | velaglucerase alfa |3911 90 99 | 892497-01-7 | azoximer bromide |IARSCRÍBHINN IILiosta na réimíreanna agus na n-iarmhíreanna lena dtuairiscítear, i gcomhcheangal le ANInna Iarscríbhinn 3 d'Iarscríbhinn I a ghabhann le Rialachán (CEE) Uimh. 2658/87, salainn, eistir nó hiodráití d'ANInna; tá na salainn, eistir agus hiodráití sin saor ó dhleacht, ar choinníoll gur féidir iad a aicmiú faoin bhfo-cheannteideal CC sé dhigit céanna leis an ANI comhfhreagrach.In ionad na dtagairtí do "Ainmneacha Neamhdhílseánacha Idirnáisiúnta (ANI) do shubstaintí cógaisíochta, Ainmneacha d'fhréamhacha agus do ghrúpaí, liosta cuimsitheach 2004" cuirtear "Ainmneacha Neamhdhílseánacha Idirnáisiúnta (ANI) do shubstaintí cógaisíochta, Ainmneacha d'fhréamhacha, do ghrúpaí agus eile, liosta cuimsitheach 2007".Cuirtear na réimíreanna agus na hiarmhíreanna seo a leanas leis an liosta:An réimír nó an iarmhír is fearr | Comhchiallach | Ainm córasach nuair atá sé éagsúil |alanetil (INNRG) | [(S)-1-ethoxy-1-oxo-propan-2-yl]amino (INNCN) |alaninate (INNRG) | L-alaninate (INNCN) |alapivoxil (INNRG) | L-alanyl, [(2,2-dimethylpropanoyl)oxy]methyl (INNCN) |aldifitox (INNRG) | (4-iminobutane-1,4-diyl)sulfanediyl[(3RS)-2,5-dioxopyrrolidine-1,3-diyl]-1,3-phenylenecarbonyl agus a dhéanann díorthach N-beansóil de phríomhghrúpa aimín de thocsain diftéire [550-L-phenylalanine] ó Corynebacterium diphtheriae-(26-560)-peptide (INNCN) |besudotox (INNRG) | Leáphróitéin L-lysyl-L-alanyl-L-serylglycylglycine (nascóir) le des-(365-380)-[Asn364,Val407,Ser515,Gln590,Gln606,Arg613]exotoxin A (Pseudomonas aeruginosa)-(251-613)-peptide (tocsain inar scriosadh iarmhair réigiún IA agus na chéad 16 iarmhar réigiún IB) (INNCN) |ceribate (INNRG) | rac-2,3-dihydroxypropyl carbonate (eistear) (INNCN) |cipecilate (INNRG) | cyclohexanecarboxylate (eistear), cyclopropanecarboxylate (eistear) (INNCN) |dalanated (INNRG) | des-B30-alanine (INNCN) |enacarbil (INNRG) | {rac-1-[(2-methylpropanoyl)oxy]ethoxy}carbonyl (INNCN) |estafenatox (INNRG) | Leáphróitéin glycylglycyl-L-proline (nascóir) le enterotoxin de chineál A (Staphylococcus aureus)-(1-33)-peptidyl-L-seryl[Ser36,Ser37,Glu38,Lys39,Ala41,Thr46,Thr71,Ala72,Ser75,Glu76,Glu78,Ser80,Ser81,Thr214,Ser217,Thr219,Ser220,Ser222,Ser224]enterotoxin type E (Staphylococcus aureus)-(32-230)-peptide (sár-antaigin shintéiseach SEA/E-120) (INNCN) |etexilate (INNRG) | ethyl, (hexyloxy)carbonyl |fosamil (INNRG) | phosphono (INNCN) |glucuronide (INNRG) | β-D-glucopyranosiduronic acid [oside] (INNCN) |medocaril (INNRG) | [(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl (INNCN) |paptox (INNRG) | próitéin PAP (Phytolacca americana frith-víreach) (INNCN) |placarbil (INNRG) | (R)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy}carbonyl) (INNCN) |Leasaítear ainm córasach na réimíre nó na hiarmhíre seo a leanas mar seo a leanas:An réimír nó an iarmhír is fearr | Comhchiallach | Ainm córasach nuair atá sé éagsúil |aritox (INNRG) | ricin A chain (INNCN) |IARSCRÍBHINN IIILiosta táirgí idirmheánacha cógaisíochta, i.e. comhdhúile a úsáidtear chun táirgí críochnaithe cógaisíochta a mhonarú, atá le cur le liosta na dtáirgí a ndéileáiltear leo ar bhonn saor ó dhleacht agus atá ar áireamh in Iarscríbhinn 6 d'Iarscríbhinn I a ghabhann le Rialachán (CEE) Uimh. 2658/87ID | Cód AC | Uimh. CAS RN | Ainm |95 | 2843 29 00 | 22199-08-2 | [4-amino-N-(pyrimidin-2(1H)-ylidene-κN1)benzenesulfonamidato-κO]airgead |428 | 2905 39 95 | 281214-27-5 | (2R,3R)-2,3-dimethylbutane-1,4-diyl bis(4-methylbenzenesulfonate) |76 | 2905 59 98 | 441002-17-1 | 4-chlorobutyl 2-nitrobenzenesulfonate |538 | 2909 30 90 | 92878-95-0 | 2-(3-chloropropoxy)-1-methoxy-4-nitrobenzene |168 | 2909 30 | 503070-57-3 | 2-({2-[(6-bromohexyl)oxy]ethoxy}methyl)-1,3-dichlorobenzene |386 | 2909 30 | 461432-23-5 | 4-(5-bromo-2-chlorobenzyl)phenyl ethyl ether |51 | 2909 49 80 | 185954-75-0 | (3R)-3-methoxydecan-1-ol |167 | 2909 49 80 | 85309-91-7 | 2-[(2,6-dichlorobenzyl)oxy]ethanol |64 | 2909 49 80 | 160969-03-9 | 2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl methanesulfonate |98 | 2909 50 00 | 167145-13-3 | 2-[2-(3-methoxyphenyl)ethyl]phenol |377 | 2910 20 00 | 15448-47-2 | (2R)-2-methyloxirane |177 | 2910 90 00 | 62600-71-9 | (2R)-2-(3-chlorophenyl)oxirane |184 | 2910 90 00 | 702687-42-1 | (2R)-2-[(5-bromo-2,3-difluorophenoxy)methyl]oxirane |88 | 2910 90 00 | 683276-64-4 | [(2R)-2-methyloxiran-2-yl]methyl 4-nitrobenzenesulfonate |191 | 2913 00 00 | 90035-34-0 | 4'-(trifluoromethyl)biphenyl-4-carbaldehyde |38 | 2914 40 90 | 17752-16-8 | (3β)-3-hydroxycholest-5-en-24-one |244 | 2914 50 00 | 974-23-2 | (3β,16α)-3-hydroxy-16,17-epoxypregn-5-en-20-one |586 | 2914 70 00 | 13054-81-4 | 4-chloro-heptane-3,5-dione |236 | 2914 70 00 | 10226-30-9 | 6-chlorohexan-2-one |122 | 2915 60 90 | 53064-79-2 | iodomethyl pivalate |426 | 2915 90 00 | 22328-90-1 | (3R)-3-methylhexanoic acid |266 | 2915 90 00 | 1069-66-5 | sodium 2-propylpentanoate |19 | 2916 20 00 | 211515-46-7 | 1-(2-ethylbutyl)cyclohexanecarbonyl chloride |32 | 2916 20 00 | 381209-09-2 | 1-(2-ethylbutyl)cyclohexanecarboxylic acid |37 | 2916 20 00 | 7077-05-6 | trans-4-(propan-2-yl)cyclohexanecarboxylic acid |531 | 2916 39 00 | 21900-39-0 | 5-fluoro-2-methylbenzoyl chloride |250 | 2916 39 00 | 17625-03-5 | sodium hydrogen 3-sulfonatobenzoate |561 | 2917 19 90 | 76-72-2 | diethyl ethyl(pentan-2-yl)propanedioate |193 | 2918 29 00 | 376592-58-4 | 5'-chloro-2'-hydroxy-3'-nitrobiphenyl-3-carboxylic acid |369 | 2918 99 90 | 709031-28-7 | (3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)(oxo)acetic acid |552 | 2918 99 90 | 35480-52-5 | 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid |559 | 2918 99 90 | 4651-67-6 | (3α,5β)-3-hydroxy-7-oxocholan-24-oic acid |264 | 2918 99 90 | 52179-28-9 | ethyl 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoate |143 | 2918 99 90 | 530141-60-7 | methyl 3-(5-{[4-(cyclopentyloxy)-2-hydroxyphenyl]carbonyl}-2-hydroxyphenyl)propanoate |114 | 2920 90 10 | 91526-18-0 | 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one |161 | 2921 49 00 | 334477-60-0 | (1R)-1-[3,5-bis(trifluoromethyl)phenyl]-N-methylethanamine |287 | 2921 49 00 | 376608-71-8 | (1R,2S)-2-(3,4-difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate |342 | 2921 49 00 | 1034457-07-2 | 2-(2,3-dihydro-1H-inden-2-yl)propan-2-amine hydrochloride |27 | 2921 49 00 | 945717-05-5 | 2-(4-chloro-3-ethylphenyl)ethanamine hydrochloride |221 | 2921 49 00 | 89-97-4 | 2-chlorobenzylamine |26 | 2921 49 00 | 945717-43-1 | N-(4-tert-butylbenzyl)-2-(4-chloro-3-ethylphenyl)ethanamine |518 | 2921 51 90 | 150812-21-8 | N4-[(4-fluorophenyl)methyl]-2-nitro-1,4-benzenediamine |343 | 2922 19 80 | 1035455-90-3 | (2R)-1-(5-bromo-2,3-difluorophenoxy)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2- yl]amino}propan-2-ol hydrochloride |397 | 2922 19 80 | 0-00-0 | [2-(chloromethyl)-4-(dibenzylamino)phenyl]methanol hydrochloride |248 | 2922 19 80 | 133-51-7 | antimonic acid -- 1-deoxy-1-(methylamino)-D-glucitol (1:1) |344 | 2922 19 80 | 1035455-87-8 | ethyl (2E)-3-(3-{[(2R)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino}-2-hydroxypropyl]oxy}-4,5-difluorophenyl)prop-2-enoate hydrochloride |185 | 2922 19 80 | 702686-97-3 | ethyl 3-(3-{[(2R)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino}-2-hydroxypropyl]oxy}-4,5-difluorophenyl)propanoate hydrochloride |36 | 2922 29 00 | 20059-73-8 | 2-[4-(aminomethyl)phenoxy]-N,N-dimethylethanamine |536 | 2922 49 85 | 848133-35-7 | (2E)-4-(dimethylamino)but-2-enoic acid hydrochloride |425 | 2922 49 85 | 610300-07-7 | (3S,5R)-3-amino-5-methyloctanoic acid |424 | 2922 49 85 | 610300-00-0 | (3S,5R)-3-amino-5-methyloctanoic acid hydrochloride |433 | 2922 49 85 | 143785-86-8 | 4-(1-aminocyclopropyl)-2,3,5-trifluorobenzoic acid |398 | 2922 49 85 | 848949-85-9 | 4-fluoro-L-leucine -- ethyl hydrogen sulfate (1:1) |475 | 2922 49 85 | 39068-93-4 | methyl 2-(dimethylamino)-2-phenylbutanoate |174 | 2922 49 85 | 168619-25-8 | methyl 3'-aminobiphenyl-3-carboxylate |565 | 2922 49 85 | 82834-12-6 | N-[(2S)-1-ethoxy-1-oxopentan-2-yl]-L-alanine |474 | 2922 49 85 | 94133-84-3 | sodium 2-amino-2-phenylbutanoate |171 | 2922 50 00 | 503070-58-4 | triphenylacetic acid -- 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1) |149 | 2924 19 00 | 62009-47-6 | 2-aminomalonamide |175 | 2924 19 00 | 7355-58-0 | N-(2-chloroethyl)acetamide |367 | 2924 29 98 | 361442-00-4 | {2-[(tert-butoxycarbonyl)amino]-3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl}acetic acid |521 | 2924 29 98 | 266993-72-0 | 2,3-diaminobenzamide dihydrochloride |532 | 2924 29 98 | 168080-49-7 | 2-chloro-4-{[(5-fluoro-2-methylphenyl)carbonyl]amino}benzoic acid |81 | 2924 29 98 | 317374-08-6 | 2-methyl-4-{[(2-methylphenyl)carbonyl]amino}benzoic acid |125 | 2924 29 98 | 143785-84-6 | 4-(1-carbamoylcyclopropyl)-2,3,5-trifluorobenzoic acid |434 | 2924 29 98 | 143785-87-9 | 4-[1-(acetylamino)cyclopropyl]-2,3,5-trifluorobenzoic acid |80 | 2924 29 98 | 108166-22-9 | 4-{[(2-methylphenyl)carbonyl]amino}benzoic acid |519 | 2924 29 98 | 150812-23-0 | ethyl {4-[(4-fluorobenzyl)amino]-2-nitrophenyl}carbamate |237 | 2924 29 98 | 22316-45-6 | ethyl 3-[(5-chloro-2-nitrophenyl)(phenyl)amino]-3-oxopropanoate |3 | 2924 29 98 | 316173-29-2 | methyl (1S,2S,3S,4R)-3-[(1S)-1-amino-2-ethylbutyl]-4-[(tert-butoxycarbonyl)amino]-2-hydroxycyclopentanecarboxylate |378 | 2924 29 98 | 1142-20-7 | N-benzyloxycarbonyl-L-alanine |102 | 2924 29 98 | 84996-93-0 | N-cyclohexyl-5-hydroxypentanamide |270 | 2924 29 98 | 579494-66-9 | propyl {4-[2-(diethylamino)-2-oxoethoxy]-3-ethoxyphenyl}acetate |533 | 2925 19 95 | 265136-65-0 | ethyl 3-amino-4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]but-2-enoate |33 | 2926 90 95 | 855425-38-6 | 1-(2-ethylbutyl)cyclohexanecarbonitrile |537 | 2926 90 95 | 846023-24-3 | 2-cyano-N-(2,4-dichloro-5-methoxyphenyl)acetamide |417 | 2926 90 95 | 591769-05-0 | 3-cyclopentylprop-2-enenitrile |50 | 2926 90 95 | 20099-89-2 | 4-(bromoacetyl)benzonitrile |54 | 2926 90 95 | 474554-45-5 | 4,5-diethoxy-3-fluorobenzene-1,2-dicarbonitrile |587 | 2926 90 95 | 79370-78-8 | 5-hydroxybenzene-1,3-dicarbonitrile |118 | 2926 90 95 | 139481-28-0 | methyl 2-{[(2'-cyanobiphenyl-4-yl)methyl]amino}-3-nitrobenzoate |182 | 2928 00 90 | 860035-10-5 | 1-({[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}oxy)ethyl 2-methylpropanoate |403 | 2928 00 90 | 910656-45-0 | 2-hydroxy-2-(trifluoromethyl)butanehydrazide |104 | 2928 00 90 | 95759-10-7 | 4-chloro-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoic acid |383 | 2928 00 90 | 473927-63-8 | ethyl (2Z)-chloro[2-(4-methoxyphenyl)hydrazinylidene]ethanoate |144 | 2928 00 90 | 158671-29-5 | N,2-dihydroxy-4-methylbenzamide |106 | 2928 00 90 | 84080-68-2 | tert-butyl (2Z)-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoate |105 | 2928 00 90 | 268544-50-9 | tert-butyl-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoate |101 | 2930 90 85 | 13459-62-6 | {2-[(4-chlorophenyl)sulfanyl]phenyl}acetic acid |20 | 2930 90 85 | 211513-21-2 | 1-(2-ethylbutyl)-N-(2-sulfanylphenyl)cyclohexanecarboxamide |181 | 2930 90 85 | 860035-07-0 | 1-{[(methylsulfanyl)carbonyl]oxy}ethyl 2-methylpropanoate |396 | 2930 90 85 | 893407-18-6 | 2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethanone |86 | 2930 90 85 | 60759-00-4 | 3,4-diethoxybenzenecarbothioamide |180 | 2930 90 85 | 21048-05-5 | N-methylbenzenecarbothiohydrazide |47 | 2931 00 95 | 13682-94-5 | (2-bromoethenyl)(trimethyl)silane |46 | 2931 00 95 | 914922-89-7 | (2R,4R)-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-N-methoxy-N,2-dimethyl-7-oxoheptanamide |44 | 2931 00 95 | 914922-88-6 | (2R,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}-N-methoxy-N,2-dimethyloct-7-enamide |45 | 2931 00 95 | 871355-80-5 | (4R)-2-bromo-7-{[tert-butyl(diphenyl)silyl]oxy}hept-1-en-4-yl 4-methylbenzenesulfonate |192 | 2931 00 95 | 89694-48-4 | (5-chloro-2-methoxyphenyl)boronic acid |359 | 2931 00 95 | 701278-08-2 | [(1R,5S)-5-[dimethyl(phenyl)silyl]-2-{[(2-methoxypropan-2-yl)oxy]methyl}cyclopent-2-en-1-yl]methanol |360 | 2931 00 95 | 701278-09-3 | {(4S,5R)-5-[(benzyloxy)methyl]-4-[dimethyl(phenyl)silyl]cyclopent-1-en-1-yl}methanol |318 | 2931 00 95 | 796967-18-5 | 1-(2-fluoro-5-methylphenyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea |52 | 2931 00 95 | 172732-52-4 | 2-(1,3,2-dioxaborinan-2-yl)benzonitrile |48 | 2931 00 95 | 185411-12-5 | methyl 3-(trimethylsilyl)pent-4-enoate |43 | 2932 19 00 | 253128-10-8 | (1S)-1,5:7,10-dianhydro-12,13-bis-O-[tert-butyl(dimethyl)silyl]-2,3,4,6,8,11-hexadeoxy-1-{2-[(2S,5S)-5-(3-hydroxypropyl)-3-methylidenetetrahydrofuran-2-yl]ethyl}-3-methyl-9-O-methyl-4-methylidene-8-[(phenylsulfonyl)methyl]-D-arabino-D-altro-tridecitol |571 | 2932 19 00 | 441045-17-6 | (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylene)-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one methanesulfonate |35 | 2932 29 85 | 916069-80-2 | (4S)-4-(fluoromethyl)dihydrofuran-2(3H)-one |554 | 2932 29 85 | 63106-93-4 | 1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one |140 | 2932 29 85 | 7734-80-7 | 2-oxo-2H-chromene-6-carboxylic acid |399 | 2932 29 85 | 0-00-0 | 4-(4-fluorophenyl)-7-(isothiocyanatomethyl)-2H-chromen-2-one |142 | 2932 29 85 | 947408-91-5 | 6-[(2,4-dihydroxyphenyl)carbonyl]-2H-chromen-2-one |141 | 2932 29 85 | 947408-90-4 | 6-[(2,4-dimethoxyphenyl)carbonyl]-2H-chromen-2-one |165 | 2932 99 00 | 452342-08-4 | (1R)-2-(benzylamino)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol |206 | 2932 99 00 | 99541-23-8 | (1R,2S,3R,4R,5R)-4-azido-2-{[(4aR,6S,7R,8S,8aR)-7,8-bis(benzyloxy)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy}-6,8-dioxabicyclo[3.2.1]oct-3-yl acetate |389 | 2932 99 00 | 461432-25-7 | (1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol |116 | 2932 99 00 | 196597-79-2 | (2E)-1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylideneethanenitrile |550 | 2932 99 00 | 3308-94-9 | 2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane |568 | 2932 99 00 | 274693-53-7 | [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]carbamate |61 | 2932 99 00 | 185954-98-7 | [6(2Z,3R)]-3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-(3-metoxydecyl)-6-methyl-2-[(1-oxo-11-octadecenyl)amino]-4-O-phosphono-β-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-α-D-glucopyranose 1-(dihydrogen phosphate) tetrasodium salt |203 | 2932 99 00 | 136172-58-2 | 1,6-di-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-D-glucopyranose |115 | 2932 99 00 | 196597-80-5 | 2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethanamine hydrochloride |354 | 2932 99 00 | 666860-59-9 | 2-amino-2-oxoethyl{3-[trans-5-(6-methoxynaphthalen-1-yl)-1,3-dioxan-2-yl]propyl}carbamate |576 | 2932 99 00 | 117661-72-0 | 5-(chloromethyl)-6-methyl-1,3-benzodioxole |405 | 2932 99 00 | 959624-24-9 | 6-(hydroxymethyl)-4-phenyl-3,4-dihydro-2H-chromen-2-ol |388 | 2932 99 00 | 960404-59-5 | but-2-yne-1,4-diol -- methyl 1-C-[4-chloro-3-(4-ethoxybenzyl)phenyl]-α-D-glucopyranoside (1:1) |13 | 2932 99 00 | 15826-37-6 | disodium 5,5'-[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(4-oxo-4H-chromene-2-carboxylate) |28 | 2932 99 00 | 204254-84-2 | ethyl (3aR,7R,7aR)-2,2-dimethyl-7-[(methylsulfonyl)oxy]-3a,6,7,7a-tetrahydro-1,3-benzodioxole-5-carboxylate |205 | 2932 99 00 | 99541-26-1 | methyl (2S,3S,4S,5S,6S)-6-{[(1S,2S,3S,4R,5R)-3-(acetyloxy)-4-azido-6,8-dioxabicyclo[3.2.1]oct-2-yl]methyl}-4,5-bis(benzyloxy)-3-hydroxytetrahydro-2H-pyran-2-carboxylate |204 | 2932 99 00 | 114869-97-5 | methyl 6-O-acetyl-4-O-(2-O-acetyl-3-O-benzyl-6-methyl-α-L-idopyranuronosyl)-3-O-benzyl-2-{[(benzyloxy)carbonyl]amino}-2-deoxy-α-D-glucopyranoside |478 | 2933 19 90 | 1035677-60-1 | (4S)-3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide 2,3-dihydroxybutanedioate |194 | 2933 19 90 | 18048-64-1 | 2-(3,4-dimethylphenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one |477 | 2933 19 90 | 1035675-24-1 | 3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide |310 | 2933 19 90 | 1028026-83-6 | 5-methyl-1-(propan-2-yl)-4-[4-(propan-2-yloxy)benzyl]-1,2-dihydro-3H-pyrazol-3-one |585 | 2933 19 90 | 473921-12-9 | 5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile |89 | 2933 29 90 | 65902-59-2 | 2-bromo-4-nitro-1H-imidazole |90 | 2933 29 90 | 57531-37-0 | 2-chloro-4-nitro-1H-imidazole |24 | 2933 29 90 | 1000164-35-1 | 3-(1,1-dimethylethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-1-(triphenylmethyl)-L-histidyl-2-methylalanyl-L-α-glutamylglycine |488 | 2933 29 90 | 152074-97-0 | L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine |489 | 2933 29 90 | 781666-30-6 | L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine tetraacetate |176 | 2933 29 90 | 451470-33-0 | methyl 3'-(2-methyl-4,5-dihydro-1H-imidazol-1-yl)biphenyl-3-carboxylate |348 | 2933 39 99 | 925978-49-0 | (+)-5-[6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl]-1-azabicyclo[3.2.1]octane |325 | 2933 39 99 | 876170-44-4 | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |1 | 2933 39 99 | 741705-70-4 | (2R)-phenyl[(2R)-piperidin-2-yl]ethanoic acid hydrochloride |162 | 2933 39 99 | 414910-13-7 | (2S)-hydroxy(phenyl)ethanoic acid -- (2R)-2-(4-fluoro-2-methylphenyl)piperidin-4-one (1:1) |314 | 2933 39 99 | 0-00-0 | (3aR,6aR)-1-(pyridin-3-yl)octahydropyrrolo[3,4-b]pyrrole 4-methylbenzenesulfonate |315 | 2933 39 99 | 370882-57-8 | (3aR,6aR)-1-(pyridin-3-yl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride |121 | 2933 39 99 | 334618-23-4 | (3R)-piperidin-3-amine dihydrochloride |579 | 2933 39 99 | 1062580-52-2 | (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |578 | 2933 39 99 | 27262-47-1 | (S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide |183 | 2933 39 99 | 105812-81-5 | [(3S,4R)-4-(4-fluorophenyl)-1-methylpiperidin-3-yl]methanol |324 | 2933 39 99 | 876068-51-8 | [(3S,4S)-4-amino-1-(5,6-dichloropyridin-3-yl)pyrrolidin-3-yl]methanol |408 | 2933 39 99 | 871022-14-9 | 1-({4-[({[2-oxo-3-(propan-2-yl)-2,3-dihydro-1H-benzimidazol-1-yl]carbonyl}amino)methyl]piperidin-1-yl}methyl)cyclobutanecarboxylic acid |549 | 2933 39 99 | 5421-92-1 | 1-(pyridin-4-yl)pyridinium chloride hydrochloride |541 | 2933 39 99 | 272776-12-2 | 1,1'-binaphthalene-2,2'-diol -- 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole (1:1) |409 | 2933 39 99 | 871022-19-4 | 1-[(4-{[(tert-butoxycarbonyl)amino]methyl}piperidin-1-yl)methyl]cyclobutanecarboxylic acid |414 | 2933 39 99 | 3613-73-8 | 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole |535 | 2933 39 99 | 179687-79-7 | 2-[(2-chloro-4-nitrophenoxy)methyl]pyridine |201 | 2933 39 99 | 122321-04-4 | 2-[methyl(pyridin-2-yl)amino]ethanol |311 | 2933 39 99 | 945405-37-8 | 2-methyl-3-[(2S)-pyrrolidin-2-ylmethoxy]pyridine 2,3-dihydroxybutanedioate |155 | 2933 39 99 | 936637-40-0 | 3,3'-piperidine-1,4-diyldipropan-1-ol 4-methylbenzenesulfonate |40 | 2933 39 99 | 88150-62-3 | 3-ethyl-5-methyl-4-(2-chlorophenyl)-2-{[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]methyl}-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate |404 | 2933 39 99 | 84100-54-9 | 4-(ethylamino)piperidine-4-carboxamide |157 | 2933 39 99 | 873546-30-6 | 4,4'-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]bis(N'-hydroxybenzenecarboximidamide) |158 | 2933 39 99 | 873546-74-8 | 4,4'-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]bis[N'-(acetyloxy)benzenecarboximidamide] |159 | 2933 39 99 | 873546-38-4 | 4,4'-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]dibenzenecarboximidamide trihydrochloride pentahydrate |156 | 2933 39 99 | 873546-80-6 | 4,4'-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]dibenzonitrile |316 | 2933 39 99 | 78750-61-5 | 4-[(3-nitropyridin-2-yl)amino]phenol |87 | 2933 39 99 | 866109-93-5 | 4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenol 4-methylbenzenesulfonate |472 | 2933 39 99 | 927889-51-8 | 4-bromo-2,6-diethylpyridine 4-methylbenzenesulfonate |272 | 2933 39 99 | 691882-47-0 | 4-hydroxybenzoic acid -- (2S,4E)-N-methyl-5-[5-(propan-2-yloxy)pyridin-3-yl]pent-4-en-2-amine (1:1) |323 | 2933 39 99 | 876068-46-1 | 5,6-dichloro-N-(2,2-dimethoxyethyl)pyridin-3-amine |220 | 2933 39 99 | 1072-98-6 | 5-chloropyridin-2-amine |85 | 2933 39 99 | 298692-34-9 | 6-(chloroacetyl)pyridine-2-carboxylic acid |349 | 2933 39 99 | 550349-58-1 | 7-chloro-3-(6-methoxypyridin-3-yl)-N,N,5-trimethyl-4-oxo-4,5-dihydro-3H-pyridazino[4,5-b]indole-1-carboxamide |160 | 2933 39 99 | 414909-98-1 | benzyl 2-(4-fluoro-2-methylphenyl)-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate |164 | 2933 39 99 | 56880-11-6 | ethyl [(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)acetate |273 | 2933 39 99 | 548797-97-3 | N-(2-{[(2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl]oxy}-4-hydroxyphenyl)acetamide |352 | 2933 39 99 | 0-00-0 | N-[(S)-1-azabicyclo[2.2.2]oct-2-yl(phenyl)methyl]-2,6-dichloro-3-(trifluoromethyl)benzamide hydrochloride |289 | 2933 39 99 | 329003-65-8 | sodium hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate hemipentahydrate |58 | 2933 49 10 | 417716-92-8 | 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide methanesulfonate |584 | 2933 49 90 | 503291-53-0 | 2-ethylbutyl (3S,4aS,6S,8aR)-6-[3-chloro-2-(1H-tetrazol-5-yl)phenoxy]decahydro-3-isoquinolinecarboxylate 4-methylbenzenesulfonate |539 | 2933 49 90 | 103733-32-0 | benzyl (3S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate hydrochloride |581 | 2933 49 90 | 503293-98-9 | (3S,4aS,6S,8aR)-6-hydroxy-2-(methoxycarbonyl)decahydroisoquinoline-3-carboxylic acid |583 | 2933 49 90 | 503290-66-2 | (3S,4aS,6S,8aR)-6-[3-chloro-2-(2H-tetrazol-5-yl)phenoxy]decahydro-3-isoquinolinecarboxylic acid hydrochloride |580 | 2933 49 90 | 134388-95-7 | (3S,4aS,8aR)-2-(methoxycarbonyl)-6-oxodecahydroisoquinoline-3-carboxylic acid -- (1R)-1-phenylethanamine (1:1) |328 | 2933 49 90 | 868210-14-4 | 4-(4-{[(2S,4R)-4-[acetyl(4-chlorophenyl)amino]-2-methyl-3,4-dihydroquinolin-1(2H)-yl]carbonyl}phenoxy)-2,2-dimethylbutanoic acid |545 | 2933 49 90 | 00-00-0 | methyl 2-[(3R)-3-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-({[1-(hydroxymethyl)cyclopropyl]methyl}sulfanyl)propyl]benzoate hydrochloride |534 | 2933 49 90 | 848133-76-6 | N-(4-chloro-3-cyano-7-ethoxyquinolin-6-yl)acetamide |479 | 2933 59 95 | 869490-23-3 | (3,3-difluoropyrrolidin-1-yl){(2S,4S)-4-[4-(pyrimidin-2-yl)piperazin-1-yl]pyrrolidin-2-yl}methanone |421 | 2933 59 95 | 941685-40-1 | (3R)-3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile |416 | 2933 59 95 | 941678-49-5 | (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile |420 | 2933 59 95 | 941685-41-2 | (3S)-3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile |394 | 2933 59 95 | 957187-34-7 | [(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]acetic acid |190 | 2933 59 95 | 356058-42-9 | {2-[(4-fluorobenzyl)sulfanyl]-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl}acetic acid |395 | 2933 59 95 | 0-00-0 | 2,3-dihydroxy-2,3-bis(phenylcarbonyl)butanedioic acid -- ethyl [(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]acetate (1:1) |407 | 2933 59 95 | 90213-66-4 | 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine |197 | 2933 59 95 | 3934-20-1 | 2,4-dichloropyrimidine |189 | 2933 59 95 | 451487-18-6 | 2-[(4-fluorobenzyl)sulfanyl]-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one |120 | 2933 59 95 | 865758-96-9 | 2-[(6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]benzonitrile |340 | 2933 59 95 | 934815-71-1 | 2-[3-(6-{[2-(2,4-dichlorophenyl)ethyl]amino}-2-methoxypyrimidin-4-yl)phenyl]-2-methylpropanoic acid phosphate |278 | 2933 59 95 | 722543-31-9 | 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate |361 | 2933 59 95 | 1032066-96-8 | 2-amino-9-{(1S,3R,4S)-3-[(benzyloxy)methyl]-4-[dimethyl(phenyl)silyl]-2-methylidenecyclopentyl}-1,9-dihydro-6H-purin-6-one -- methanesulfonate (2:1) |406 | 2933 59 95 | 540737-29-9 | 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate |400 | 2933 59 95 | 1137917-12-4 | 3-{[6-(ethylsulfonyl)pyridin-3-yl]oxy}-5-{[(2S)-1-hydroxypropan-2-yl]oxy}benzoic acid -- 1,4-diazabicyclo[2.2.2]octane (2:1) |422 | 2933 59 95 | 941685-39-8 | 3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile |419 | 2933 59 95 | 941685-27-4 | 4-(1H-pyrazol-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine |365 | 2933 59 95 | 1780-26-3 | 4,6-dichloro-2-methylpyrimidine |567 | 2933 59 95 | 145783-14-8 | 4,6-dichloro-5-nitro-2-(propylsulfanyl)pyrimidine |423 | 2933 59 95 | 3680-69-1 | 4-chloro-7H-pyrrolo[2,3-d]pyrimidine |215 | 2933 59 95 | 61379-64-4 | 4-cyclopentylpiperazin-1-amine |219 | 2933 59 95 | 55112-42-0 | 4-methylpiperazine-1-carbonyl chloride hydrochloride |338 | 2933 59 95 | 0-00-0 | 5-(benzylamino)-2-(3-methoxyphenyl)-7-(4-methylpiperazin-1-yl)[1,2,4]triazolo[1,5-a]quinoline-4-carbonitrile -- (2E)-but-2-enedioate (2:1) hydrate |471 | 2933 59 95 | 55293-96-4 | 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde |288 | 2933 59 95 | 179688-01-8 | 7-(benzyloxy)-6-methoxyquinazolin-4(3H)-one |198 | 2933 59 95 | 444731-74-2 | N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine |355 | 2933 59 95 | 0-00-0 | N-(5-fluoro-3-methyl-1H-indol-1-yl)-4-methyl-2-(pyridin-2-yl)pyrimidine-5-carboxamide |484 | 2933 79 00 | 586414-48-4 | (-)-3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-dimethylbenzamide |486 | 2933 79 00 | 425663-71-4 | (1S)-1-amino-3-methyl-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one hydrochloride |34 | 2933 79 00 | 813452-14-1 | (4S)-1-[(2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one dihydrochloride |77 | 2933 79 00 | 5162-90-3 | 3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine |384 | 2933 79 00 | 536760-29-9 | 3-chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one |78 | 2933 79 00 | 4876-10-2 | 4-(bromomethyl)quinolin-2(1H)-one |69 | 2933 79 00 | 5057-12-5 | 4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione |72 | 2933 79 00 | 54197-66-9 | 6-hydroxy-3,4-dihydroquinolin-2(1H)-one |75 | 2933 79 00 | 22246-18-0 | 7-hydroxy-3,4-dihydroquinolin-2(1H)-one |380 | 2933 79 00 | 536759-91-8 | ethyl 1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate |382 | 2933 79 00 | 503614-91-3 | ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate |485 | 2933 79 00 | 586379-61-5 | methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate |368 | 2933 99 80 | 709031-45-8 | (1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate |376 | 2933 99 80 | 649735-46-6 | (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol |276 | 2933 99 80 | 51077-14-6 | (2S)-1-(tert-butoxycarbonyl)azetidine-2-carboxylic acid |277 | 2933 99 80 | 631916-97-7 | (2S)-N-{4-[(Z)-amino(methoxyimino)methyl]benzyl}-1-{(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyethanoyl}azetidine-2-carboxamide --benzenesulphonic acid (1:1) |564 | 2933 99 80 | 80875-98-5 | (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid |313 | 2933 99 80 | 948846-40-0 | (2S,3S)-2,3-bis[(phenylcarbonyl)oxy]butanedioic acid -- ethyl (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (1:1) |302 | 2933 99 80 | 1000164-36-2 | (5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S)-5-(3-amino-3-oxopropyl)-20-benzyl-23-[(2S)-butan-2-yl]-14,38-bis{4-[(tert-butoxycarbonyl)amino]butyl}-29-{[1-(tert-butoxycarbonyl)-1H-indol-3-yl]methyl}-17-(3-tert-butoxy-3-oxopropyl)-1-(1H-fluoren-9-yl)-8,11,26,41,41-pentamethyl-32-(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33,36,39-tridecaoxo-35-(propan-2-yl)-2-oxa-4,7,10,13,16,19,22,25,28,31,34,37,40-tridecaazadotetracontan-42-oic acid |529 | 2933 99 80 | 22162-51-2 | 1-(2-nitrobenzyl)-1H-pyrrole-2-carbaldehyde |410 | 2933 99 80 | 35681-40-4 | 1-(propan-2-yl)-1,3-dihydro-2H-benzimidazol-2-one |522 | 2933 99 80 | 166170-15-6 | 1-(tert-butoxycarbonyl)-2-methyl-D-proline |322 | 2933 99 80 | 796967-16-3 | 1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea |321 | 2933 99 80 | 0-00-0 | 1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea hydrochloride |196 | 2933 99 80 | 444731-72-0 | 2,3-dimethyl-2H-indazol-6-amine |415 | 2933 99 80 | 19686-05-6 | 2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole |524 | 2933 99 80 | 912444-00-9 | 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide |523 | 2933 99 80 | 912445-36-4 | 2-[(2S)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide dihydrochloride |481 | 2933 99 80 | 163457-23-6 | 3,3-difluoropyrrolidine hydrochloride |65 | 2933 99 80 | 239463-85-5 | 3-{5-[(2R)-2-aminopropyl]-7-cyano-2,3-dihydro-1H-indol-1-yl}propyl benzoate (2R,3R)-2,3-dihydroxybutanedioate |150 | 2933 99 80 | 55321-99-8 | 3-oxo-3,4-dihydropyrazine-2-carboxamide |375 | 2933 99 80 | 952490-01-6 | 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl 2,2-dimethylpropanoate |274 | 2933 99 80 | 942436-93-3 | 4-amino-8-(2,5-dimethoxyphenyl)-N-propylcinnoline-3-carboxamide |275 | 2933 99 80 | 942437-37-8 | 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide |285 | 2933 99 80 | 288385-88-6 | 4-fluoro-2-methyl-1H-indol-5-ol |582 | 2933 99 80 | 503293-47-8 | 5-(2-chloro-6-fluorophenyl)-2H-tetrazole |71 | 2933 99 80 | 73963-42-5 | 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole |271 | 2933 99 80 | 606143-52-6 | 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide |347 | 2933 99 80 | 0-00-0 | 5-fluoro-1-(3-fluorobenzyl)-N-(1H-indol-5-yl)-1H-indole-2-carboxamide |373 | 2933 99 80 | 872206-47-8 | 5-methyl-4-oxo-1,4-dihydropyrrolo[2,1-f][1,2,4]triazin-6-yl 2,2-dimethylpropanoate |151 | 2933 99 80 | 259793-88-9 | 6-bromo-3-oxo-3,4-dihydropyrazine-2-carboxamide |562 | 2933 99 80 | 1137606-74-6 | 6-fluoro-3-oxo-3,4-dihydropyrazine-2-carbonitrile -- N-cyclohexylcyclohexanamine (1:1) |482 | 2933 99 80 | 261953-36-0 | 6-iodo-1H-indazole |73 | 2933 99 80 | 80076-47-7 | 8,9-difluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid |188 | 2933 99 80 | 52602-39-8 | 9H-carbazol-4-ol |235 | 2933 99 80 | 145641-35-6 | benzyl (2S,3aR,7aS)-octahydro-1H-indole-2-carboxylate hydrochloride |540 | 2933 99 80 | 87269-87-2 | benzyl (2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylate hydrochloride |21 | 2933 99 80 | 1012065-72-3 | ethyl 2-amino-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline-3-carboxylate |563 | 2933 99 80 | 131707-24-9 | ethyl 6-bromo-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate |124 | 2933 99 80 | 105152-95-2 | ethyl 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate |117 | 2933 99 80 | 139481-44-0 | methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate |393 | 2933 99 80 | 0-00-0 | methyl 1-tert-butyl-2-hydroxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylate |555 | 2933 99 80 | 21688-11-9 | N2-[(benzyloxy)carbonyl]-L-glutaminyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-prolyl-L-leucylglycinamide |370 | 2933 99 80 | 361440-67-7 | tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate |371 | 2933 99 80 | 709031-38-9 | tert-butyl (2S)-2-carbamoyl-2,3-dihydro-1H-pyrrole-1-carboxylate |366 | 2933 99 80 | 709031-43-6 | tert-butyl [(1S)-2-[(1S,3S,5S)-3-cyano-2-azabicyclo[3.1.0]hex-2-yl]-1-(3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)-2-oxoethyl]carbamate |588 | 2933 49 90 | 936359-25-0 | methyl 2-((R)-3-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(((1-(hydroxymethyl)cyclopropyl)methyl)sulfanyl)propyl)benzoate |341 | 2934 10 00 | 110130-88-6 | (2Z)-[(acetyloxy)imino](2-amino-1,3-thiazol-4-yl)ethanoic acid |547 | 2934 10 00 | 68672-66-2 | (2Z)-{[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino}[2-(tritylamino)-1,3-thiazol-4-yl]ethanoic acid |202 | 2934 10 00 | 291536-35-1 | (5Z)-5-(4-fluorobenzylidene)-1,3-thiazolidine-2,4-dione |362 | 2934 10 00 | 302964-24-5 | 2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide |339 | 2934 10 00 | 866920-24-3 | 3-[2-chloro-4-({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methoxy)phenyl]-1,2,4-oxadiazol-5(4H)-one |353 | 2934 10 00 | 752253-39-7 | 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(prop-2-yn-1-yl)-1,3-thiazol-2-amine |57 | 2934 10 00 | 914361-45-8 | L-lysine -- {[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1- yl)butan-2-yl]oxy}methyl dihydrogen phosphate -- ethanol (1:1:1) |363 | 2934 10 00 | 302964-08-5 | N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide |107 | 2934 10 00 | 127660-04-2 | sodium (2Z)-(2-amino-1,3-thiazol-4-yl)(hydroxyimino)ethanoate |135 | 2934 99 90 | 17381-54-3 | (1-benzothiophen-5-yl)acetic acid |60 | 2934 99 90 | 630100-90-2 | (1R)-1,2-anhydro-4-C-{(1E,3E)-4-[(1S,2S,3E,5R,6R,9R)-5-(1-carboxylato-4-cycloheptylpiperazin-2-yl)-6,9-dihydroxy-2,6-dimethyl-11-oxooxacyclododec-3-en-1-yl]penta-1,3-dien-1-yl}-3,5-dideoxy-1-[(2R,3S)-3-hydroxypentan-2-yl]-D-erythropentitol |283 | 2934 99 90 | 220099-91-2 | (2R)-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-furo[2,3-b]pyridine] |282 | 2934 99 90 | 220100-81-2 | (2R)-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-furo[2,3-b]pyridine] (S,S)-2,3-dihydroxybutanedioate |29 | 2934 99 90 | 161599-46-8 | (2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-2-fluoro-5-methyltetrahydrofuran-3,4-diyl diacetate |30 | 2934 99 90 | 690270-65-6 | (2R,3S,4R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-azido-2-{[(2-methylpropanoyl)oxy]methyl}tetrahydrofuran-3,4-diyl bis(2-methylpropanoate) hydrochloride |392 | 2934 99 90 | 265121-04-8 | (3-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(2-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid -- 1-deoxy-1-(methylamino)-D-glucitol (1:2) |126 | 2934 99 90 | 163680-80-6 | (3S)-10-[1-(acetylamino)cyclopropyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid |544 | 2934 99 90 | 132335-46-7 | (3S)-N,N-dimethyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine |345 | 2934 99 90 | 133413-70-4 | (3S,6R,9S,12R,15S,18R,21S,24R)-6,18-dibenzyl-4,10,12,16,22,24-hexamethyl-3,9,15,21-tetrakis(2-methylpropyl)-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclotetracosane-2,5,8,11,14,17,20,23-octone |169 | 2934 99 90 | 503068-36-8 | (5R)-3-(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one |166 | 2934 99 90 | 452339-73-0 | (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one |470 | 2934 99 90 | 877130-28-4 | (6R)-6-cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one |543 | 2934 99 90 | 132335-44-5 | (S)-3-(dimethylamino)-1-(thiophen-2-yl)propan-1-ol |31 | 2934 99 90 | 812647-80-6 | {(2R,3S,4R,5R)-2-azido-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-bis[(phenylcarbonyl)oxy]tetrahydrofuran-2-yl}methyl 3-chlorobenzoate |551 | 2934 99 90 | 00-00-0 | 1-(1-{4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butyl}-1,2,3,6-tetrahydropyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one |418 | 2934 99 90 | 1029716-44-6 | 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole |358 | 2934 99 90 | 165172-60-1 | 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione -- 1-methylpyrrolidin-2-one (1:1) |139 | 2934 99 90 | 519187-97-4 | 1-[3-(2-benzo[b]thien-5-ylethoxy)propyl]-3-azetidinol -- (2Z)-2-butenedioate (1:1) |49 | 2934 99 90 | 127000-90-2 | 1-{[(2R,3S)-2-(2,4-difluorophenyl)-3-methyloxiran-2-yl]methyl}-1H-1,2,4-triazole |332 | 2934 99 90 | 710281-33-7 | 2-({[(1R,3S)-3-{[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}cyclohexyl]oxy}methyl)-6-methylbenzoic acid |136 | 2934 99 90 | 96803-30-4 | 2-(1-benzothiophen-5-yl)ethanol |59 | 2934 99 90 | 913695-00-8 | 2-[({4-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethylpyridin-2-yl}methyl)sulfinyl]-1Hbenzimidazole, salann sóidiam (1:1) |286 | 2934 99 90 | 376608-74-1 | 2-{[(3aR,4S,6R,6aS)-6-{[5-amino-6-chloro-2-(propylsulfanyl)pyrimidin-4-yl]amino}-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy}ethanol |55 | 2934 99 90 | 474554-48-8 | 2-bromo-1-[3-tert-butyl-4-methoxy-5-(morpholin-4-yl)phenyl]ethanone |148 | 2934 99 90 | 530141-72-1 | 3-(5-{[4-(cyclopentyloxy)-2-hydroxyphenyl]carbonyl}-2-[(3-hydroxy-1,2-benzoxazol-6-yl)methoxy]phenyl)propanoic acid |138 | 2934 99 90 | 519188-55-7 | 3-[2-(1-benzothiophen-5-yl)ethoxy]-1-(3-hydroxyazetidin-1-yl)propan-1-one |137 | 2934 99 90 | 519188-42-2 | 3-[2-(1-benzothiophen-5-yl)ethoxy]propionic acid |566 | 2934 99 90 | 753015-42-8 | 3-{(E)-2-[(3R)-pyrrolidin-3-yl]ethenyl}-5-(tetrahydro-2H-pyran-4-yloxy)pyridine |557 | 2934 99 90 | 26638-53-9 | 3-chloro-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide |153 | 2934 99 90 | 499785-81-8 | 3-oxo-4-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-3,4-dihydropyrazine-2-carboxamide |154 | 2934 99 90 | 356782-84-8 | 3-oxo-4-(β-D-ribofuranosyl)-3,4-dihydropyrazine-2-carboxamide |211 | 2934 99 90 | 6504-57-0 | 4-[3-hydroxy-3-phenyl-3-(thiophen-2-yl)propyl]-4-methylmorpholin-4-ium methyl sulfate |329 | 2934 99 90 | 871484-32-1 | 4-[4-({3-[(4-deoxy-4-fluoro-b-D-glucopyranosyl)oxy]-5-(propan-2-yl)-1H-pyrazol-4-yl}methyl)phenyl]-N-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]butanamide |575 | 2934 99 90 | 166964-09-6 | 4-chloro-3-methyl-1,2-oxazol-5-amine |93 | 2934 99 90 | 655233-39-3 | 4-nitrobenzyl(6R,7R)-7-amino-8-oxo-3-[(2S)-tetrahydrofuran-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride |542 | 2920 90 85 | 89729-09-9 | 5,7-dioxa-6-thiaspiro[2.5]octane-6-oxide |172 | 2934 99 90 | 388082-75-5 | 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furancarboxaldehyde 4-methylbenzenesulfonate (1:1) |134 | 2934 99 90 | 4923-87-9 | 5-bromo-1-benzothiophene |146 | 2934 99 90 | 947408-95-9 | 6-(bromomethyl)-2-triphenylmethyl-1,2-benzisoxazol-3(2H)-one |145 | 2934 99 90 | 947408-94-8 | 6-methyl-2-trityl-1,2-benzoxazol-3(2H)-one |110 | 2934 99 90 | 67978-05-6 | diphenylmethyl(2R)-3-methyl-2-[(1R,5S)-3-(4-methylphenyl)-7-oxo-4-oxa-2,6-diazabicyclo[3.2.0]hept-2-en-6-yl]but-3-enoate |357 | 2934 99 90 | 1001859-46-6 | DNA (veicteoir phlasmaideach shintéiseach pCOR a réalaíonn leáphróitéin ina bhfuil peiptíd de chomhartha beta d'inteirféarón daonna ag a bhfuil tosca fáis d'fhibreablast daonna ar a bhfuil an t-aimínaigéad 21- 154) |326 | 2934 99 90 | 665058-78-6 | DNA, d(T-sp-C-G-sp-T-sp-C-G-sp-T-sp-T-sp-T-sp-T-sp-G-sp-A-sp-C-G-sp-T-sp-T-sp-T-sp-T-sp-Gsp- T-sp-C-G-sp-T-sp-T) |401 | 2934 99 90 | 923591-06-4 | methyl (5R,7S,10S)-10-tert-butyl-15,15-dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxylate |577 | 2934 99 90 | 59337-92-7 | Methyl 3-(chlorosulfonyl)thiophene-2-carboxylate |147 | 2934 99 90 | 947409-01-0 | methyl 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(2-triphenylmethyl-1,2-benzisoxazol-3(2H)-on- 6-yl)methoxy]phenyl]propionate |212 | 2934 99 90 | 85006-31-1 | Methyl 3-amino-4-methylthiophene-2-carboxylate |280 | 2934 99 90 | 893428-72-3 | N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine -- (2E)-2-butenedioate (1:2) |18 | 2934 99 90 | 390800-88-1 | N,N',N''-(boroxin-2,4,6-triyltris{[(1S)-3-methylbutane-1,1-diyl]imino[(2S)-1-oxo-3-phenylpropane-1,2-diyl]})tripyrazine-2-carboxamide |99 | 2934 99 90 | 112913-94-7 | N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}acetamide |412 | 2934 99 90 | 120788-03-6 | S-[(1R,3S)-1-oxidotetrahydrothiophen-3-yl] ethanethioate |402 | 2935 00 90 | 1198178-65-2 | (1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethylcyclopropanaminium 4-methylbenzenesulfonate |556 | 2935 00 90 | 39570-96-2 | (2R)-3-(benzylsulfanyl)-N-[(2S)-1-{[(2S,3S)-1-hydrazinyl-3-methyl-1-oxopentan-2-yl]amino}- 3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-{[(4-methylphenyl)sulfonyl]amino}propanamide |79 | 2935 00 90 | 24310-36-9 | 1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one |346 | 2935 00 90 | 0-00-0 | 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide di[(2E)-but-2-enedioate] hydrate |281 | 2935 00 90 | 941690-55-7 | 3-[(methylsulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide |199 | 2935 00 90 | 6973-09-7 | 5-amino-2-methylbenzenesulfonamide |82 | 2935 00 90 | 193686-76-9 | 7-chloro-1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one |130 | 2935 00 90 | 123664-84-6 | N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide |133 | 2935 00 90 | 149457-03-4 | N-[4-(N-formylglycyl)-5-hydroxy-2-phenoxyphenyl]methanesulfonamide |132 | 2935 00 90 | 149456-98-4 | N-[4-(N-formylglycyl)-5-methoxy-2-phenoxyphenyl]methanesulfonamide |319 | 2935 00 90 | 141450-48-8 | N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxybenzenesulfonamide hydrochloride |391 | 2935 00 90 | 289042-10-0 | N-{5-[(diphenylphosphoryl)methyl]-4-(4-fluorophenyl)-6-(propan-2-yl)pyrimidin-2-yl}-N-methylmethanesulfonamide |187 | 2939 99 00 | 7689-03-4 | (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione |239 | 2939 99 00 | 477-29-2 | Colchicoside |173 | 2940 00 00 | 604-69-3 | 1,2,3,4,6-penta-O-acetyl-β-D-glucopyranose |333 | 2940 00 00 | 647834-15-9 | 2-(4-methoxybenzyl)thiophen-3-yl β-D-glucopyranoside |127 | 2941 90 00 | 76610-92-9 | (6R,7R)-7-({N-[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]-D-threonyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |570 | 3907 20 99 | 913976-27-9 | poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy, diester le 21N6, 21’N6-[[(N2, N6-dicarboxy-L-lysyl-β-alanyl)imino]bis(1-oxo-2, 1-ethanediyl)]bis[N-acetylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(1-naphthalenyl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-N-methylglycyl-L-lysinamide] cyclic (6→15), (6’→15’) bis(disulfide) |IARSCRÍBHINN IVLiosta na dtáirgí idirmheánacha cógaisíochta, i.e. comhdhúile a úsáidtear chun táirgí críochnaithe cógaisíochta a mhonarú, agus atá le baint ó liosta na dtáirgí a ndéileáiltear leo ar bhonn saor ó dhleacht agus atá ar áireamh in Iarscríbhinn 6 d'Iarscríbhinn I a ghabhann le Rialachán (CEE) Uimh. 2658/87 ós rud é go bhfuil siad curtha ar liosta na dtáirgí a ndéileáiltear leo ar bhonn saor ó dhleacht agus atá ar áireamh in Iarscríbhinn 3 d'Iarscríbhinn I a ghabhann le Rialachán (CEE) Uimh. 2658/87Cód AC | Uimh. CAS RN | Ainm |2915 39 00 2937 29 00 | 7753-60-8 | 17-alpha-hydroxy-3,20-dioxopregna-4,9(11)-diene-21-yl acetate féach anecortave (ANI) |2920 90 85 | 163133-43-5 | 4-(nitrooxy)butyl (2S)-2-(6-methoxy-2-naphthyl)propanoate féach naproxcinod (ANI) |2924 29 98 | 194085-75-1 | 2-(2-chlorophenyl)-2-hydroxyethyl carbamate féach carisbamate (ANI) |2933 39 99 | 103129-82-4 | 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate féach levamlodipine (ANI) |2933 39 99 | 319460-85-0 | N-methyl-2-{[3-((E)-2-pyridin-2-ylvinyl)-1H-indazol-6-yl]sulfanyl}benzamide féach axitinib (ANI) |2934 10 00 | 302962-49-8 | N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)thiazole-5-carboxamide féach dasatinib (ANI) |2934 99 90 | 143491-57-0 | (2R,5S)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one féach emtricitabine (ANI) |2934 99 90 | 98819-76-2 | (2S)-2-[(S)-(2-ethoxyphenoxy)phenylmethyl]morpholine féach esreboxetine (ANI) |2934 99 90 | 475479-34-6 | (2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid féach aleglitazar (ANI) |2934 99 90 | 377727-87-2 | 2-(2-furyl)-7-(2-{4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl}ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[2,3-c]pyrimidin-5-amine féach preladenant (ANI) |2934 99 90 | 189003-92-7 | 2-{7-fluoro-2-oxo-4-[2-(4-thieno[3,2-c]pyridin-4-ylpiperazin-1-yl)ethyl]quinolin-1(2H)-yl}acetamide féach trelanserin (ANI) |2934 99 90 | 134379-77-4 | 4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1H)-one féach dexelvucitabine (ANI) |2934 99 90 | 518048-05-0 | potassium 4-[N-(2-fluorobenzyl)carbamoyl]-1-methyl-2-[1-methyl-1-(5-methyl-1,3,4-oxadiazole-2-carboxamido)ethyl]-6-oxo-1,6-dihydropyrimidine-5-olate féach raltegravir (ANI) |2935 00 90 | 170569-88-7 | 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzene-1-sulfonamide féach mavacoxib (ANI) |2935 00 90 | 186497-07-4 | N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide féach zibotentan (ANI) |[1] IO L 256, 7.9.1987, lch. 1.